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Epstein-Barr virus (EBV) infects more than 90% of human population worldwide
and has the ability to persist for the lifetime of the infected person. Although EBV
infection is most often asymptomatic, the virus causes infectious mononucleosis (IM)
in teenagers and young adults. Within a host, EBV can alternate infection between
B cells and epithelial cells. The presence of EBV DNA inside these infected cells
has been associated with diﬀerent types of cancers. Many aspects of EBV infection
within a host including the switching infections between cell types, the eﬀects of
this switching, the factors involve in regulation of the persistent infection, and what
parts of the regulation can go wrong that induce diﬀerent types of disease, are not
well understood. The aim of our work is studying these aspects using the tools of
mathematical models. We ﬁrst explore the role of EBV glycoprotein gp42 in the virus
entry into target cells. Our models support the role of cooperation of multiple viral
glycoproteins in virus entry and suggest that the intracellular interactions of gp42 with
HLA class II in B cells may disrupt gp42 function. We then study the dynamics of
EBV infection within a host and show that EBV switching host cell tropism shapes
the persistence, evolution, and coexistence of the virus infection. Our model of the
within host dynamics suggests that the age dependence of IM can be explained by
the host antibodies that enhance infections of epithelial cells and the cross-reactive
responses of aggressive but functionally ineﬀective T cells previously created by other
infections. We also investigate the association of EBV infection with the development
of nasopharyngeal carcinoma (NPC), a cancer of epithelial cells in the pharynx. Our
model predicts a threshold of the number of eﬀector T cells below which a bifurcation
leads to a jump from a low to high level of latently infected epithelial cells that can
greatly elevate the risk of NPC development. Our model also produces the patterns of
age-incidence curves that have been observed in low risk and high risk populations.
For my family
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Epstein-Barr virus (EBV) was ﬁrst isolated in 1964 from tumor samples taken
from patients with Burkitt’s lymphoma (BL) [22]. The virus belongs to the family of
Herpesviridae, infects over 90% of humans worldwide and can persist for the lifetime
of the person [74]. EBV is transmitted by intimate contact, through saliva and
oropharyngeal secretion [3]. Most people infected with EBV are asymptomatic (i.e.
healthy carriers), especially if infected in early childhood. However in the US and many
other Western countries, primary infection with EBV is often delayed until young adult
ages, where as many as 50% of cases develop into infectious mononucleosis (IM) [85].
Within a host, EBV infects two major cell types, B cells and epithelial cells [33].
The ability of virus to alternate tropism between cell types helps to both maintain
a long-term infection within one host and to amplify its population for transmission
to new hosts [4]. Persistent infection with EBV has been associated with diﬀerent
types of cancers including the B cell cancers Burkitt’s lymphoma (BL) and Hodgkin’s
lymphoma (HL), and the epithelial cell cancer nasopharyngeal carcinoma (NPC). EBV
infection in immunosuppressed people such as transplant recipients and HIV patients
can lead to other types of lymphomas [15].
The abilities of EBV to establish a long-term infection within a host, to persist
through the lifetime of the host, but also to escape regulation and trigger cancer
development motivate and inspire the work in this thesis.
We begin with models of viral entry that control how the virus attacks diﬀerent
cell types. We then study how the use of these diﬀerent cells aﬀects viral shedding,
persistence, and evolution. Next, we extend these models to study two common
pathologies associated with EBV. Infection mononucleosis occurs during primary infec-
tion and involves inappropriate immune responses. Nasopharyngeal carcinoma occurs
2only afters many decades of infection, triggered by a failure of viral regulation and an
interaction with the immune system.
1.1 Virus entry: viral glycoprotein gp42, the
switch of tropism
Within a host, EBV infects two major cell types, B cells and epithelial cells. Entry
of the virus into B cells and epithelial cells occurs through diﬀerent routes, determined
by glycoproteins on the surface of the virus. The viral glycoprotein gp42 plays a key
role in the switch of tropism. To enter a B cell, gp42, in the form of a three part
complex with gH and gL, needs to bind to HLA class II molecules on B cell to trigger
fusion. Epithelial cells do not express HLA class II; not only is gp42 unnecessary, it
also has an inhibiting eﬀect on EBV infection of epithelial cells [4, 36, 37].
Intracellular interaction with HLA class II molecules produced in B cells can lead
to degradation of some gp42. Hence, EBV viruses derived from B cells, which we
term “B cell viruses,” express 2- to 5-fold lower levels of gp42 compared to virus
derived from epithelial cells, or “epithelial cell virus.” Intriguingly, this decrease in
gp42 level leads to 30 to 100-fold decrease in the infectivity of B-cell virus to B cells,
compared to epithelial-cell virus [4]. This nonlinear relationship suggests the possibility
of cooperation among multiple viral gH/gL/gp42 complexes for fusion to B cells, or
disrupted function of the remaining gp42 in viruses derived from B cells. In our study,
we explore these two hypotheses using mathematical models of protein binding kinetics
for surface interactions between viral glycoproteins and target cell receptors for virus
entry, and models for intracellular interaction between gp42 and HLA class II in B
cells.
The glycoprotein gp42 is related to certain types of natural killer cell receptors
that can recognize HLA class II molecules, with 22% to 28% sequence identity. It
is thought that gp42 may have been originally acquired by EBV from a host, and
diverged through many generations of viral evolution and selection [59]. The structure
of gp42 and its essential role in virus entry into B cells have been intensively studied
[47, 48, 71, 79, 81]. However, the exact mechanisms of how EBV uses gp42 to trigger
fusion still await further studies. The goal of our models is to give insights into these
3further studies (Chapter 2).
1.2 Regulation of virus dynamics and the association
with infectious mononucleosis
1.2.1 EBV latent and lytic infections
After a virus successfully enters a naive B cell (one that has not been exposed to
antigen), it downregulates the expression of its own genes to only about 9 out of more
than 100 genes that control progression through the diﬀerent stages of latent infection.
EBV uses combinations of these genes to drive infected cells through a similar pathway
of a normal B cell activation process. A normal B cell, upon stimulation by antigen,
will become activated and proliferate. These proliferating B cells need help from T
cells in order to diﬀerentiate into memory cells. With antigen stimulation, memory B
cells can diﬀerentiate into plasma cells that release antibodies [85].
When EBV infects a naive B cell, it uses the combination of genes called the“growth
program” to activate and transform the cell into the ﬁrst stage of latent infection.
This transformed B cell can proliferate. Often, proliferating cells are recognized and
eliminated by the immune response. Those that survive enter the memory stage as the
virus switches to use another gene combination called the“default program.” Once the
cell reaches the memory stage, in vitro study has shown that EBV expresses none of
its genes, the “latency program” [35]. EBV is thought to use this strategy to escape
immune recognition and to help the virus survive inside an infected cell. The number of
infected cells within a host is estimated to be in the range of 5−3, 000 per 107 memory
B cells in the blood [49]. The same range is estimated for the number of infected
memory B cells in the oropharynx. The total number of infected cells per person is
estimated to be around 0.5× 106 [85]. The infected cell has the same characteristics of
a resting memory B cell except that EBV genomes exist inside its nucleus as a separate
episome. As members of memory B cell population, infected cells circulate within the
blood and can be found in the lymphoid tissues [33].
Infected memory B cells are under the same regulation as normal memory B cells.
At any given time, 2-3% of infected memory B cells in the blood are undergoing cell
division [85]. Memory B cells use this homeostatic mechanism to maintain the cell
4population at a stable level. The virus EBNA1 gene is expressed at this stage so that the
virus genome can replicate with the cell [35]. Normal memory B cells can diﬀerentiate
into plasma cells to produce antibodies in response to secondary infection. Infected
memory B cells can diﬀerentiate into lytically infected cells found in the lymphoid
tissues of the oropharynx. These infected cells have similar characteristics to plasma
B cells [49]. How EBV switches on its lytic replication within the latent infected cell
is still not completely understood. In vitro studies on the Akata cell line show that
the lytic cycle can be quickly (in order of minutes) switched on by cross linking of the
antigen receptor on these cells [85]. In vivo, the diﬀerentiation of a memory B cell into
a plasma cell requires days [85]. Lytic replication is a key step that helps spread the
virus to new hosts and maintain EBV infection within one host.
Lytic EBV infection is divided into three phases: immediate early (IE), early, and
late [41]. EBV expresses most of its genes during the stages of lytic infection. First,
IE genes are expressed for viral proteins to be produced. Early genes are then turned
on to encode viral proteins involved in replication. After lytic replication, late genes
are expressed to encode proteins that are needed for the viral genome to be packaged
into the free virions that burst out of the cell. Plasma-like B-cell derived virus may get
ampliﬁed through lytic infection of epithelial cells before virus genomes are shed into
the saliva. It remains unknown whether viruses produced from the lytic infection need
to infect more B cells to keep the infection cycle going on or if homeostasis of memory
B cells alone is enough to maintain the low level of latent infection within the host.
During the latent cycle, EBV expresses only a few of its genes, thus avoiding
the immune recognition. Three of the genes expressed during diﬀerent stages of
the latent infection, LMP1, LMP2, and EBNA1, help the virus to manipulate the
immune response. LMP1 and LMP2 provide necessary signals for diﬀerentiation into
the memory stage [55]. EBNA1, on the other hand, interferes with the process of
proteasomal degradation of proteins to limit the amount of viral antigens presented by
HLA class I and reducing the CD8+ T cell response. Throughout the lytic cycle, EBV
expresses more than 60 proteins, many of which downregulate the immune response
[60].
51.2.2 T cell response
The T cell response to most viral infections includes two cell types: CD4+ helper
T cells and CD8+ cytotoxic T cells. An in vitro study demonstrated that CD4+ T
cells can inhibit the proliferation of newly infected B cells [63]. Most studies of T cell
responses to EBV infection have focused on CD8+ responses in IM patients. CD8+ T
cells that respond to EBV infection can kill infected cells and control the growth of
EBV transformed B cells and epithelial cells through the secretion of interferon gamma
(IFNγ) [60]. Diﬀerent lineages of CD8+ T cells respond to lytic and latent infection
[33].
During acute IM infection, speciﬁc response to EBV lytic epitopes can make up
1%-40% of the total CD8+ population [33]. These aggressive T cell responses are
the main reasons causing IM symptoms. These activated CD8+ T cells are antigen
stimulated and have a high turnover rate. These highly aggressive lytic responses are
quickly reduced during the resolution of acute IM. Speciﬁc responses to latent infection
are smaller in magnitude. Latent-speciﬁc CD8+ T cells also reduce their population
after IM but at a lower rate than lytic-speciﬁc CD8+ T cells. In the long term, both
lytic and latent EBV speciﬁc CD8+ T cells make up 1-5% [60] of the CD8+ T cell
population.
1.2.3 Mathematical modeling of virus dynamics and modiﬁed
application to study persistent viral infection
The basic mathematical model of virus dynamics has been built and modiﬁed to
study viral infections including HIV, HBV, and HCV [61, 65, 68]. This basic model
describes the population dynamics of viral infection within an infected host [66, 68].
The model tracks three state variables: uninfected susceptible cells X, infected cells Y ,
and free virus particles V . Uninfected cells are produced or replenished with a constant
rate π and die with rate δ. Free virus particles encounter and successfully infect cells
at rate β. Infected cells produce virus at rate k and die at rate a. Virus particles are
removed at rate μ to give the system
dX
dt
= π − δX − βXV
6dY
dt
= βXV − αY (1.1)
dV
dt
= kY − μV.
This nonlinear system has two possible steady states. At the virus-free equilibrium,
clearance occurs and both infected cells and virus populations die out: X∗ = π/δ, Y ∗
= 0, and V ∗ = 0. At the second steady state, all three populations coexist. Stability
analysis of these steady states gives the condition
βπk
αδμ
< 1 for clearance to be the
only steady state and to be stable. When
βπk
αδμ
> 1, the second steady state exists
and is stable. The quantity
βπk
αδμ
is the number of newly infected cells that arise from
one infected cell when introduced into a population of uninfected cells. It is called the
basic reproduction number, R0, a key quantity in epidemiology.
Extending this model to also track the number of latently infected cells, a mathe-
matical model of the dynamics of EBV has been built to study the T cell response to
a persistent virus infection [18],
dX
dt
= π − δX − βXV
dY
dt
= βXV + L+ rY − (λ+ α)Y
dV
dt
= kY − μV (1.2)
dL
dt
= λY − (+ γ)L.
This model assumes that infection of target cells (X) gives rise to lytically (i.e. pro-
ductively) infected cells (Y ). These lytically infected cells can proliferate with rate r,
turn into latently infected cells (L) at rate λ, produce virus at rate k and die at rate
α. Latently infected cells can be activated to turn into lytically infected cells at rate 
and die at rate γ.
In addition to including multiple stages of infection, the model can include a T cell
response. In a simpliﬁed version, only lytically infected cells are recognized and killed
by T cells. This eﬀect can be included in the death rate α. In combination with a
model of eﬀector T cells activation from naive cells, the model can be used to study how
7the T cell response develops during a persistent infection. This model, however, does
not distinguish target cells as B cells or epithelial cells. The assumption that lytically
infected cells can produce virus without going through latent stages of infection applies
only to infection of epithelial cells. The assumption that these productively infected
cells can proliferate and become latently infected cells does not reﬂect the biology of
EBV infection of either cell type.
Besides this mathematical model, the dynamics of EBV infection of B cells and
the T cell response have been explored using the agent-based models C-ImmSim and
PathSim [9, 78]. PathSim includes the interactions of viruses, uninfected, latently
infected and lytically infected B cells, and T cells. Infection of naive B cells gives
rise to the population of latently infected B cells that can proliferate and be killed by
T cells. These latently infected B cells can hide from T cell recognition by entering
the blood compartment which represents the memory stage. Coming out of the blood
compartment, these B cells can be activated to become lytically (or productively)
infected cells which in which virus can replicate and exit the cell. Lytically infected
cells can be recognized and killed by T cells. Simulations of PathSim have been used
to investigated if clearance of EBV infection is possible and to identify the critical
parameters that control the dynamics of infection. PathSim shows that maintenance
of a latent infection within the memory B cell population is a key requirement for EBV
to persist within a host. The dynamics of infection prove to be especially sensitive
to variation in the reactivation rate of lytic infection from infected memory B cells.
A small increase in this rate causes the number of infected cells to expand quickly
and remain at a high level. However, this sensitivity may be due to the lack of T cell
proliferation in PathSim. Although the interactions between agents in PathSim include
a detailed description of the biology of B cell infection, infection of epithelial cells is
not included. Furthermore, the model can be studied only via computer simulation
without the aid of analytical methods that can provide better understanding of its
behavior.
Our models build upon the interaction between viruses and B cells described in
PathSim, but add T cell proliferation and infection of epithelial cells to develop a
8mathematical model of EBV infection that extends the basic model of viral infection
(Chapter 3). Our model can explore how the dynamics of EBV infection are shaped by
the presence of two cell types, and the possible eﬀects of switching infection between
cell types on virus shedding, persistent infection, and evolution.
1.2.4 Infectious mononucleosis
Adolescents and young adults infected with EBV may develop infectious mononu-
cleosis (IM) with symptoms including fever and fatigue that may last from a few weeks
up to several months [3, 15]. Aggressive T cell responses with expansion in the number
of CD8+ T cells, especially against EBV lytic proteins, are the main cause for these
symptoms. Three hypotheses have been proposed to explain the prevalence of IM in
this age group and its absence in children. The ﬁrst hypothesis is that a young adult
may be initially infected by a high dose of virus [33]. In young adults, transmission
often occurs through close oral contact, which may transmit large number of viruses.
The second hypothesis concerns the complexity of the preexisting CD8+ repertoire. In
children, the memory T cell repertoire is simple and most of the CD8+ responses to
viral infection is from activation of naive cells. After the infection is controlled, these
activated cells either die out or become memory cells. As people get older, the memory
CD8+ repertoire becomes more complex due to exposure to multiple pathogens. In
older people, the CD8+ response to the primary EBV infection may come primarily
from cross-reactive memory CD8+ T cells created in response to infections by other
viruses. These cross-reactive responses may not be as eﬃcient as the responses from the
activation of naive cells [85]. The ﬁnal hypothesis involves the role of host saliva and
antibodies to EBV proteins that increase with age [21, 67]. Antibodies may actually
promote infection of epithelial cells [4], altering the typical balance between cell types
and inducing a high level of CD8+ T cell response against lytic infection. To investigate
these three hypotheses, we modify the basic model described in Chapter 3 to allow
cross-reactive T cell responses and include the eﬀects of host saliva and antibodies on
the infection of the two cell types (Chapter 4).
91.3 EBV and cancer: nasopharyngeal carcinoma
Studies have linked EBV infection with several cancers, presumably because EBV
has proteins, such as LMP1 and EBNA1, that can cause cell proliferation and inhibit
apoptosis. In fact, EBV was ﬁrst isolated from a Burkitt’s lymphoma (BL) tumor, a
cancer of B cells and that mostly occurs in children from Central Africa [24]. EBV
infection together with malaria infection are thought to contribute to the pathogenesis
of BL [24]. Hodgkin’s lymphoma (HL), a malignant disease of Hodgkin/Reed Sternberg
(HRS) cells that originate from B cells, is another cancer associated with EBV. Not all
HL cases are EBV related. The link of EBV infection to HL is through the ﬁnding of
the EBV genome in up to 40% of HL tumors. Post-IM patients have been shown to be
at higher risk of getting EBV positive HL compared to healthy carriers [34]. The risk
of EBV negative HL does not increase after IM. It is assumed that B cells infected by
EBV can escape the cellular regulation process in favor of growth and survival which
induces the development of lymphoma. In addition, an impaired immune response may
fail to control the growth of the infected cell population, allowing the lymphoma to
progress quickly to HL within a few years after getting IM [34].
EBV is strongly associated with nasopharyngeal carcinoma (NPC), with all tumor
samples of undiﬀerentiated type III containing EBV DNA. NPC is a cancer of epithelial
cells in the nose and pharynx with highest incidence in Southern China and Southeast
Asia [70]. Infection of epithelial cells normally results in lytic infection where viral
particles are released and cells die. Genetic changes and diet may give rise to a pool of
epithelial cells that are susceptible to EBV latent infection [11, 70]. Immunoglobulin
A (IgA) to EBV viral capsid antigen and especially to viral glycoprotein 350 can
enhance EBV infection of the predisposed epithelial cells [53, 83]. Expression of
EBV latent genes, such as LMP1 and EBNA1, within the latently infected epithelial
cells contributes to cell proliferation, survival, and accumulation of regulatory T cells
[50, 86], which can accelerate tumor development. NPC tumors represent the clonal
expansion of an EBV latently infected epithelial cell [70]. CD8+ T cells can recognize
and kill these latently infected tumor cells [51]. However, host genetics, accumulation
of regulatory T cells, and EBV strains with certain base pair deletion in LMP1 genes
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can aﬀect the functionality of these CD8+ T cells [70].
We focus our study on the regulation of EBV infection in the population of latently
infected epithelial cells local to the pharynx, assuming that the risk of getting NPC is
proportional to the number of these latently infected epithelial cells (Chapter 5). Our
model, describing the dynamics of these latently infected cells, adapts a model built to
describe the dynamics of tumors being attacked by eﬀector CD8+ T cells [30]. We use
the model to study critical breakdown in regulation of the infection that can lead to a
high level of latently infected epithelial cells, and hence an increased risk of NPC.
1.4 Concluding remarks
Since its discovery more than 40 years ago, EBV has attracted many empirical stud-
ies of its ability to persist within one host and its association with cancers. However,
EBV infects only humans and a limited range of host cells, and lacks a good animal
models to investigate EBV infection in vivo [72]. Most hypotheses and conclusions
about EBV infection are based on studies of cell cultures in epithelial and B cell lines.
Viral loads and infected cell data must be obtained from saliva and blood collected
from infected people. Many aspects of EBV infection still remain open questions. This
is why mathematical models can be helpful. Exploring the dynamics of EBV infection
with mathematical models can help to formulate questions and provide insight for
speciﬁc biological study of EBV infection in the laboratory. Our goals are to use
mathematical models to investigate (1) the mechanism of EBV entry and switching
infections between cell types, (2) how infections of the two cell types are regulated and
the role of alternating tropism on virus shedding, persistent infection, and evolution,
(3) factors aﬀecting the dynamics of infection that may lead to IM, and (4) association
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2.1 Abstract
Epstein-Barr virus (EBV) persists in B cells, but sheds via epithelial cells. Viruses
emerging from one cell type preferentially infect the other type, with a mechanism
involving a set of glycoproteins on the viral envelope. The glycoprotein gp42 plays a
key role in the switch by binding to HLA-II. HLA-II is expressed by B cells, but not
epithelial cells. Due to intracellular association of gp42 with HLA-II molecules in B
cells, virus derived from B cells expresses 2- to 5-fold decreased level of gp42 and is 30- to
100-fold less eﬃcient in infecting B cells than virus derived from epithelial cells. In this
study, we use mathematical models to investigate two diﬀerent hypotheses explaining
this nonlinear relationship between gp42 level and its eﬀects on the infectivity of viruses
to B cells. In the ﬁrst hypothesis, we assume intracellular interactions of gp42 with
HLA-II in B cells may modify and disrupt functions of gp42 in fusion. Our numeri-
cal result shows that only a small fraction of the three-part complexes gH/gL/gp42
produced in B cells has gp42 that has not interacted with HLA-II molecules. In
the second hypothesis, cooperation of multiple gH/gL/gp42 complexes are required
for virus fusion. Our model demonstrates that the more gH/gL/gp42 complexes are
needed, the greater the decrease in infectivity of B-cell virus to B cells. These results
suggest the value of further studies to investigate functional diﬀerences between gp42
expressed on B-cell and epithelial-cell viruses.
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2.2 Introduction
Within a host, Epstein-Barr virus (EBV) infects two major cell types, B cells and
epithelial cells. EBV uses diﬀerent complexes of glycoproteins to enter and infect
the two cell types. The virus uses gp350, the most abundant glycoprotein on its
envelope, to bind CD21 on B cells [4]. The viral entry into a B cell then requires
binding of the three-part glycoprotein gH/gL/gp42 complex to HLA-II, human genes
that encode antigen presenting proteins on the surface of antigen presenting cells.
Another glycoprotein gB is also invovled in a way that has not been fully understood
[48]. Epithelial cells express CD21 at a low level and do not express HLA-II. Hence,
EBV gp350 and gp42 are not needed for viral entry into epithelial cells. Fusion of virus
with an epithelial cell requires only the complexes gH/gL and gB binding to integrins
expressed on the cell [4, 12]. The presence of gp42 reduces the infectivity of EBV to
epithelial cells [4].
As gH, gL, and gB are required for EBV fusion with both epithelial cells and B cells,
the viral glycoprotein gp42 serves as the molecular switch that EBV uses to alternate
infections between the two cell types. This glycoprotein has separate binding sites for
gH and HLA-II molecule [48]. In a B cell, gp42 interacts with HLA-II, and can become
a target for degradation. Viruses derived from B cells thus express low levels of gp42.
Because epithelial cells do not express HLA-II, no such intracellular interactions occur
and viruses derived from epithelial cells express 2- to 5-fold higher levels of gp42 than
viruses derived from B cells [4, 25]. As a result, B-cell derived viruses are approximately
5 times more eﬃcient at infecting epithelial cells than epithelial-cell derived viruses.
More surprisingly, epithelial-cell viruses are 30-100 times more eﬃcient in infecting B
cells than viruses derived from B cells [4, 36]. The 2- to 5-fold increase in gp42 level
is ampliﬁed to a 30- to 100-fold increase in the infectivity of epithelial-cell virus. Our
aim is to use mathematical models to study this nonlinear relationship between the
gp42 level and the infectivity of viruses. The structure and diﬀerent mutational forms
of gp42 have been intensively studied and the requirement of this protein for fusion
of B cells has been conﬁrmed [48, 79, 81]. However, the mechanism of how it triggers
fusion and the number of gH/gL/gp42 complexes involved in fusion remain unknown
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[4, 79].
We propose models to investigate two hypotheses on mechanisms causing the dif-
ference between the eﬃciency of B-cell and epithelial-cell viruses in infecting B cells.
The ﬁrst hypothesis concerns how the association of gp42 with HLA-II molecules inside
B cells may aﬀect the functions of gp42 in fusion. The glycoprotein gp42 is produced
late in the lytic cycle when virus is replicated within an infected cell. After translation,
gp42 is glycosylated and modiﬁed before being transported to cell membrane and
incorporated into the viral envelope [71]. HLA-II molecules are also being produced in
B cells and gp42 has been shown to interact with these molecules throughout diﬀerent
stages of their maturation [4, 71]. We hypothesize that intracellular association of gp42
with HLA-II molecules may not only degrade some gp42, but may also interfere with
glycosylation and modiﬁcation of this protein in B cells. Changing a few residues in
certain parts of gp42 can disrupt its function in inducing fusion [81]. Virus derived
from B cells may not only have a 2- to 5-fold decrease in the gp42 level, but also express
gp42 with disrupted ability to trigger fusion.
The second hypothesis suggests that multiple viral gH/gL/gp42 complexes must
bind to HLA-II for successful fusion with B cells [4]. A small increase in the level of
gp42 could then lead to a multiplicative eﬀect on the infectivity of the virus.
2.3 Intracellular association of gp42 with
HLA-II molecules
2.3.1 Epithelial cells
There is no production of HLA-II molecules inside epithelial cells. Our model
(Figure 2.1(a)) tracks the levels of gp42 (G), gH/gL (H), and the complex gH/gL/gp42
(CH) resulting from the association of gp42 with gH/gL using the following equations
dG
dt
= αG + k
−
1 CH − k1GH − dGG
dH
dt
= αH + k
−
1 CH − k1GH − dHH (2.1)
dCH
dt











































































Figure 2.1. Production of gp42 (G) and the kinetics of its interaction with gH (H) and
HLA-II (A). (a) In epithelial cells with no production of HLA-II. (b) In B cells assuming
interaction with HLA-II has no eﬀect on gp42 function. (c) In B cells assuming interaction
with HLA-II can modify gp42 (Gm and CHm) and aﬀect its function in fusion.
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The model assumes gp42 and gH/gL are produced with constant rates αG and αH ,
respectively. They are removed or degraded at rates dG and dH respectively. The gp42
can bind gH with rate k1 that gives rise to the complex gH/gL/gp42, which unbinding
rate is k−1 .
It has been shown that gp42 binds gH/gL with strong aﬃnity (Kd = 8.5 nM) [47].
At a low 10 nM concentration of gp42 and gH/gL, the same study observed a binding
rate (kob) between these two proteins of 0.908 min
−1 and a half life of the gH/gL/gp42








to calculate the values for k1 = 0.0491 min
−1 · nM−1 and k−1 = 0.4172 min−1. Using
the half life information, the degradation rate of gH/gL/gp42 complex can also be
calculated, dCH = 0.07 min
−1. We assume the half life of gp42 is similar to gH/gL/gp42.
The production rates of gp42 and gH/gL, (αG and αH), and the degradation rate of
gH/gL (dH) are estimated to give the observed ratio gp42:gH (CH :H) in the literature
[4]. A summary of parameter deﬁnition and values using for the model of gp42
interaction in epithelial cells can be found in Table 2.1.
Table 2.1. Parameter deﬁnitions and values for production and interaction of gp42
with gH/gL (Equation 2.1 and 2.2).
Parameter Value Units Deﬁnition
αG 1 nM/min Production rate of gp42
k1 0.0491 [47] 1/(nM · min) Binding rate of gp42 to gH
k−1 0.4172 [47] 1/min Unbinding rate of gp42 from
the complex gH/gL/gp42
dG 0.07 1/min Death rate of gp42
αH 2.5 nM/min Production rate of gH/gL
dH 0.035 1/min Death rate of gH/gL
dCH 0.07 [47] 1/min Death rate of gH/gL/gp42
16
2.3.2 B cells
HLA-II molecules are produced inside B cells and associate with gp42 throughout
diﬀerent stages of the glycoprotein maturation. In addition to gp42, gH/gL, and
the complexes gH/gL/gp42, the model also tracks the levels of HLA-II molecules
(A) and the complexes of gp42 and gH/gL/gp42 binding to HLA-II (CA and CAH)
(Figure 2.1(b)). Assuming the intracellular association of gp42 with HLA-II in B cells
may lead to modiﬁcation of gp42 that can aﬀect its function in fusion, the model tracks
these modiﬁed gp42 (Gm) and its form in complex with gH/gL (CHm) separately from
the ones that have not associated with HLA-II (Figure 2.1(c)). The model, thus,
includes the eight equations
dG
dt
= ηαG + k
−
1 CH − k1GH − k2GA− dGG
dGm
dt
= k−2 CA + k
−
1 CHm − k1GmH − k2GmA− dGGm
dH
dt
= ηαH + k
−
1 (CH + CHm + CAH)− k1(G+Gm + CA)H − dHH
dA
dt
= αA + k
−
2 (CA + CAH)− k2(G+Gm + CH + CHm)A− dAA (2.2)
dCH
dt
= k1GH − k−1 CH − k2CHA− dCHCH
dCHm
dt
= k1GmH + k
−





1 CAH − k1CAH − k−2 CA − dCACA
dCAH
dt
= k1CAH + k2(CH + CHm)A− k−1 CAH − k−2 CAH − dCAH .
B cells produce more viral DNA than epithelial cells [4, 25], describing by using
a factor of η = 5 to increase gp42 and gH/gL production in B cells. The half life of
HLA-DR, a type of HLA class II that is strongly associated with gp42, was estimated
to be approximately 60 min [17]. Interaction with gp42 does not aﬀect the level of
HLA-II being expressed on the cell surface [71]. We thus calculate dA = 0.0116 min
−1,
and let dCA and dCAH take on the same values. Individuals express diﬀerent subsets
of HLA-II alleles which have diﬀerent susceptibility to gp42 binding. For example,
gp42 binds HLA-DR with strong aﬃnity while it does not bind that well to HLA-DQ
[4, 27]. We assume the binding between gp42 and HLA-II, on average, is weaker than
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the binding between gp42 and gH/gL. We let the on and oﬀ rates of gp42 binding to
HLA-II, k2 and k
−
2 , to take on the baseline values that are smaller than the values of
k1 and k
−
1 . We will vary the values of k2 and the production rate of HLA-II, αA, to
study their eﬀects on the levels of gp42 being expressed as a three-part gH/gL/gp42
complexes on the viral envelope, CH and CHm. A summary of parameter deﬁnition and
values using for the model of gp42 interactions in B cells can be found in Tables 2.1
and 2.2.
2.3.3 Results
We use these models (Equations 2.1 and 2.2) to study the eﬀects of intracellular
association of gp42 with HLA-II on the level and function of gp42 being produced. In-
teraction with HLA-II can lead to a decreased ratio of gH/gL/gp42 to gH/gL expressed
by virus produced in B cells (Figure 2.2). This decrease is only about 2-fold if we do
not distinguish gp42 that have and have not interacted with HLA-II. Because only a
small fraction of the three-part complexes include gp42 that has not interacted with
HLA-II, the assumption that association with HLA-II can modify gp42 and disrupt its
Table 2.2. Parameter deﬁnitions and values for gp42 interactions with HLA-II in B
cells (Equation 2.2).
Parameter Value Range Units Deﬁnition
η 5 no unit Factor of increased viral
production in B cells




1 /5 1/min Unbinding rate of gp42
from the complex of
gp42 and HLA-II
αA 4 (0 - 10) nM/min Production rate of
HLA-II
dA 0.0116 [17] 1/min Death rate of HLA-II
dCA dA [71] 1/min Death rate of
gp42/HLA-II
dCAH dA [71] 1/min Death rate of
gH/gL/gp42/HLA-II
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(a) Epithelial cells (b) B cells











































Figure 2.2. Two-part and three-part complexes being produced in epithelial cells (a)
and B cells (b). The dashed lines indicate the level of gH/gL (H). The dotted line
indicates the level of gH/gL/gp42 (CH) being produced in B cells with gp42 that has not
interacted with HLA-II. The dash-dotted line indicates the level of gH/gL/gp42 (CHm)
being produced in B cells with gp42 that has interacted with HLA-II (a) Epithelial
cells. (b) B cells. Ratio1 describes the ratio of total number of three-part complexes to
two-part complex at equilibrium. Ratio2 describes the ratio of only three-part complex
with gp42 that has not interacted with HLA-II to two-part complexes.
function in fusion can explain the 30- to 100- fold decreased infectivity of B-cell virus
compared with epithelial-cell virus.
Variation in the production rate of HLA-II of the infected cells and especially in the
binding rate of gp42 to HLA-II molecules can greatly aﬀect the content of functional
gp42 on the viral envelope (Figure 2.3). This implies that virus will express high level
of functional gp42 if it is derived from B cells that gp42 does not bind well with the cell
HLA-II molecules. The virus, hence, will not be eﬃcient at infecting epithelial cells.
This is consistent with the observation in vitro [4].
2.4 Cooperation of multiple gH/gL/gp42 complexes
In the second hypothesis, we investigate the mechanism of viral entry into a B cell.
In vitro study of EBV infection of B cells indicates that the ﬁrst event of viral entry
into a B cell is binding of EBV gp350 to the receptor CD21 on the cell [37]. Because
gp350 is the most abundant glycoprotein on the viral envelope, we assume this step
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Figure 2.3. Eﬀects of intracellular association of gp42 with HLA-II in B cells on the
ratio of three-part to two-part complexes gH/gL/gp42: gH/gL. The solid lines indicate
the ratio of total three-part complexes (CH + CHm : H). The dash lines indicate the
ratio of only three-part complexes with gp42 have not interacted with HLA-II (CH : H).
(a) The ratios as a function of production of HLA-II (αB). (b) The ratios as a function
of the binding rate of gp42 with HLA-II (k2).
is not rate-limiting and begin our model by tracking the complexes of B cells with
viruses attached to CD21 (C). Our model describes the kinetics of these complexes of
B cells and viruses through diﬀerent stages of viral entry. We assume no death of B
cells during the process of viral entry and hence C remains constant and a B cell is
in one of ﬁve stages: C0, C1, C2, C3, or Cf (Figure 2.4). The initial stage with only
viral gp350 binding to CD21 is represented by C0. The next stages in viral entry is
for the gH/gL/gp42 (G4) complexes to bind to HLA-II on the cell (C1 and C2). Our
key assumption is that two gH/gL/gp42 complexes must bind to HLA-II molecules on
a B cell before the involvement of gB (GB) creates the complex (C3) that can induce
fusion (Cf ). We analyze the case where two complexes of gH/gL/gp42 are needed. The
model can be extended for any number of gH/gL/gp42 requiring for viral entry.
We let Pi = Ci/C to describe the portion of initial complexes (C) in each stage i,
where i = 0, 1, 2, 3, or f , the kinetics of B cells going through diﬀerent stages of viral
entry take the following form
dP0
dt
= k−1GP1 − k1GG4P0
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Figure 2.4. Kinetics of B cell going through diﬀerent stages of viral entry. C0 is
complex of B cell and attached virus with only gp350 binding to CD21. C1 and C2
are complexes of B cell and and attached virus with one and two gH/gL/gp42 binding
to HLA-II molecules (after binding of gp350 to CD21), respectively. C3 is complex of
B cell and attached virus with gB involvement to trigger fusion. Cf represents virus
fusion with B cell (virus successfully enters the cell).
dP1
dt
= k1GG4P0 + k
−
2GP2 − k−1GP1 − k2GG4P1
dP2
dt
= k2GG4P1 + k
−
BP3 − k−2GP2 − kBGBP2 (2.3)
dP3
dt




Here, P0 + P1 + P2 + P3 + Pf = 1. We assume that the number of viruses is greater
than the number of B cells , where each virus expresses multiple gH/gL/gp42 (G4) and
gB (GB) complexes.
We can use this system of equation to examine how the amount of three-part
gH/gL/gp42 complex (G4) aﬀects successful fusion to B cells (Pf ) at any ﬁxed value
of time. The numerical solution of Pf (Equation 2.3) as a function of G4 is given in
Figure 2.5(a). There exists a range of G4 level (G4 level is small) such that a small
change in this level can greatly aﬀect the level of fusion. A summary of parameter
deﬁnition can be found in Table 2.3.
The model (Equation 2.3) can be extended to study the case where more than two
gH/gL/gp42 complexes are needed. We compare the eﬀects of the amount of three-part
gH/gL/gp42 complexes (G4) on the level of fusion to B cells for the cases n = 2 and
n = 3 (Figure 2.5(b)). When three-part complexes are rare, a small increase (3-fold)
can greatly increase virus fusion to B cells (Figure 2.5(c)). This eﬀect is intensiﬁed
with the increased number of gH/gL/gp42 needed for cooperation (large n). If multiple
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Table 2.3. Parameter deﬁnitions for the model of viral entry (Equation 2.3).
Parameter Deﬁnition
kiG Binding rate of the ﬁrst gH/gL/gp42 to HLA-II
1
k−1G Unbinding rate of gH/gL/gp42 from the
ﬁrst gH/gL/gp42/HLA-II complex 2
k2G Binding rate of the second gH/gL/gp42 to HLA-II
1
k−nG Unbinding rate of gH/gL/gp42 from the second
gH/gL/gp42/HLA-II complex 2
kB Binding rate of gB to its receptor on B cell
1
k−B Unbinding rate of gB to its receptor
2
kf Rate of fusion
2
1 These parameters have the unit of min−1nM−1
2 These parameters have the unit of min−1
three-part gH/gL/gp42 complexes are indeed require for EBV fusion with B cells, the
observation of 2 to 5-fold increase in the level of gp42 leading to 30 to 100-fold increase
in the infectivity of virus to B cells can be explained better with the case n = 3
(Figure 2.5(d)).
2.5 Discussion
The switch of infection between cell types is crucial to viral persistence and maybe
diseases, and that it can be explained through intracellular interaction and the kinetic
of binding. The 2- to 5-fold increase in gp42 level on the viral envelope inhibits
infection of epithelial cells proportional to the level, but increases infection of B cells
disproportionally, 30- to 100-fold. In this study, we have used mathematical models to
study two diﬀerent hypotheses on the eﬀect of gp42 level on the infectivity of virus to
B cells.
The ﬁrst hypothesis assumes intracellular association of gp42 with HLA-II not only
degrades some gp42, but also modiﬁes gp42 and reduces its function in fusion. This
hypothesis can explain the 30- to 100-fold decrease in infectivity of B-cell virus to
B cells in comparison with epithelial-cell virus. Indirect support of this hypothesis
comes from the observation that changing only a few residue in critical region of gp42
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Figure 2.5. Eﬀects of the level of three-part complexes gH/gL/gp42 (G4) on level
of fusion (Pf ). The dashed lines are for the case n = 2 while the solid lines are for
the case n = 3. (a) Level of successful fusion (Pf ) as a function of gH/gL/gp42
(G4). (b) Level of Pf as a function of G4, comparing the the cases n = 2 (dashed
line) and n = 3 (dotted line). (c) The diﬀerence of increase in fusion due to 3-fold
increase in the level of gH/gL/gp42 as a function of initial level of gH/gL/gp42. (d)
Ratio of increase in fusion due to 3-fold increase in the level of gH/gL/gp42 as a
function of initial level of gH/gL/gp42. Parameter values used for these analyses are
kiG = 0.00098 nM
−1min−1(i = 1, or 2), k−iG = 0.83 min
−1, knG = 0.049 nM−1min−1
(n = 2, or 3), k−nG = 0.042 min
−1, kB = 0.0049 nM−1min−1, k−B = 0.0417 min
−1,
kf = 0.033 min
−1, t = 300 min.
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protein can disrupt its function in fusion [81]. Our result suggests the value of further
studies to investigate functional diﬀerences between gp42 expressed on B-cell and on
epithelial-cell virus.
Our second hypothesis assumes that multiple three-part complexes gH/gL/gp42 on
the viral envelope must bind to HLA-II molecules on B cells in order for viral glyco-
protein gB to bind and trigger fusion. We ﬁnd that multiple gH/gL/gp42 complexes
must be needed to explain the 30 to 100-fold increase in viral infectivity. The higher
the number of required gH/gL/gp42, the better the increase in the viral infectivity can
be explained. The exact number of gH/gL/gp42, however, still relies on further studies
of the kinetics of gH/gL/gp42 on the viral envelope binding to HLA-II on B cells with
data on diﬀerent binding aﬃnity of multiple complexes. If this hypothesis holds for the
requirement of multiple gH/gL/g42 for fusion, it suggests gp42 might serve as a great
potential target for vaccine or therapy in prevention and treatment of EBV infection.
The observation that gp42 serves as a molecular switch of tropism for EBV [4] is of
great potential interest for studies of evolution of EBV tropism, the mechanisms of virus
entry, and the association of EBV with diﬀerent types of cancer of B cells and epithelial
cells. Obtaining understanding of what can aﬀect the gp42 level being expressed on
the viral envelope and how this level aﬀects infectivity and preferred tropism of EBV
is critical. If the ﬁrst hypothesis holds for the eﬀect of the intracellular association
of gp42 with HLA-II on the function of gp42, host genetics may play a key role in
susceptibility of cell lines to EBV and the course of the long-term infection.
In individuals with HLA-II alleles that interact weakly with gp42, virus derived
from B cells would express high level of gp42 and EBV long term infection might focus
mainly on B cells. Moreover, the level of infected B cells would be low in this case
because gp42 does not bind well to HLA-II. If an individuals carries HLA-II alleles that
strongly interact with gp42, EBV can be very eﬀective at switching infection between B
cells and epithelial cells. In this case, this individual may be more susceptible to EBV
infection and the long-term infection shifts to involve more infection of epithelial cells.
Indeed, diﬀerent studies have linked speciﬁc types of HLA-II alleles to EBV associated
diseases including infectious mononucleosis, Hodgkin’s disease, and nasopharyngeal
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carcinoma [2, 31]. Future work can use mathematical models to address how these
shifts of tropism aﬀect the dynamics of long-term persistence of EBV infection and
association of the infection with cancer of B cells and epithelial cells.
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Epstein-Barr virus (EBV) infects and can persist in a majority of people worldwide.
Within an infected host, EBV targets two major cell types, B cells and epithelial
cells, and viruses emerging from one cell type preferentially infect the other. We use
mathematical models to understand why EBV infects epithelial cells when B cells serve
as a stable refuge for the virus and how switching between infecting each cell type
aﬀects virus persistence and shedding. We propose a mathematical model to describe
the regulation of EBV infection within a host. This model is used to study the eﬀects of
parameter values on optimal viral strategies for transmission, persistence, and intrahost
competition. Most often, the optimal strategy to maximize transmission is for viruses
to infect epithelial cells, but the optimal strategy for maximizing intrahost competition
is for viruses to mainly infect B cells. Applying the results of the within-host model, we
derive a model of EBV dynamics in a homogeneous population of hosts that includes
superinfection. We use this model to study the conditions necessary for invasion and
coexistence of various viral strategies at the population level. When the importance




Epstein-Barr virus (EBV) belongs to the herpesvirus family, infects over 90%
of humans worldwide and persists for the lifetime of the person [74]. Most individuals
infected with EBV are asymptomatic, but the virus has been associated with many
diseases and cancers including infectious mononucleosis (IM), Burkitt’s lymphoma,
Hodgkin’s lymphoma, and nasopharyngeal carcinoma (NPC). EBV is transmitted by
intimate contact, mainly through saliva and oropharyngeal secretion [3]. The virus
primarily targets two cell types, B cells and epithelial cells. In B cells, EBV can
establish a long-term infection. Once successfully entering a naive B cell, EBV can
drive an infected B cell through diﬀerent stages of latent infection where the viral
genome remains inside the cell. The virus turns oﬀ most of its gene expression when
an infected cell diﬀerentiates into the memory stage. Within an infected memory B cell,
EBV stays quiescent, and remains invisible to the immune response. These infected
memory B cells can be activated and become plasma-like B cells within which virions
can replicate and burst out (lytic infection) [85]. In epithelial cells, an EBV infection
often results in virus replication and production. Latent infection of epithelial cells is
rare and has been observed only in the case of NPC.
In vitro, viruses that emerge from one cell type preferentially infect the other [4].
The viral glycoprotein gp42 on EBV’s envelope serves as the molecular switch that EBV
uses to alternate infections between the two cell types. This viral protein is required for
infection of B cells, but inhibits infection of epithelial cells. In B cells, gp42 interacts
with HLA class II, human genes that encode antigen presenting proteins on the surface
of antigen presenting cells, and becomes a target for degradation. Hence, viruses
produced by B cells express low levels of gp42. Epithelial cells do not express HLA
class II and hence viruses produced by epithelial cells express high levels of gp42 [4].
As a result, viruses emerging from B cells are approximately ﬁve times more eﬃcient
at infecting epithelial cells than the viruses emerging from epithelial cells, which are
100 times more eﬃcient in infecting B cells than viruses derived from B cells [36].
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The viral infection of B cells and the maintenance of a persistent infection within
the host have been intensively studied [75]. The dynamics of EBV infection of B
cells and the T cell responses have been investigated using simulations of agent-based
models, C-ImmSim and PathSim [9, 78]. The infection of epithelial cells, however, has
not been included in these models. Simulations of these models reproduce qualitative
features of real infections where the maximum number of infected cells and viruses occur
sometimes between one to a few weeks after initial infection, and a persistent infection
is established within months. PathSim shows that EBV cannot result in a persistent
infection unless it can maintain a latent infection within the memory B cell population.
The simulation results of this agent-based model also highlight the sensitivity of the
dynamics of infection to variation in the reactivation rate of lytic infection from infected
memory B cells. A small increase in this rate causes the number of infected cells to
expand quickly and remain at a high level [78]. However, the sensitivity may be due
to the lack of T cell expansion and proliferation in this agent-based model.
A mathematical model describing the within-host dynamics of EBV infection has
been constructed to study the T cell responses to persistent virus [18]. This model uses
ordinary diﬀerential equations to track the number of latently and lytically infected
cells, viruses, and T cells. However, it does not identify a speciﬁc class of target cells,
such as B cells or epithelial cells. The model allows newly infected cells to produce
viruses without going through latent stages of infection and allows lytically infected
cells to become latently infected. The ﬁrst of these two assumptions only applies for
infection of epithelial cells. The second assumption does not reﬂect the biology of EBV
infection of either cell type. Diﬀerential equation models have also been developed
to study the dynamics of other herpesvirus infections like cytomegalovirus (CMV or
HHV-5) [92] and HHV-6 [90]. Both CMV and HHV-6 can infect a wide range of cells
in human and share the ability to establish persistent infection within the host cells
with other herpesviruses [57, 95].
In this study, we develop and analyze mathematical models describing the within-
host and between-host dynamics of infection to explore the eﬀects of switching between
host cell types on viral shedding, persistence, and evolution. Within a host, EBV must
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infect B cells to establish a long-term infection. However, infection of epithelial cells
plays an important role in transmitting the infection. In fact, EBV is transmitted
mainly through saliva and most viruses found in the saliva of infected hosts show
characteristics of deriving from epithelial cells [44]. We propose a mathematical model
to capture the within-host dynamics of virus and host-cell interaction, including the
dynamics of epithelial cell infection. Assuming EBV can modify its ability to infect B
cells and epithelial cells, we use this model to compute viral strategies that maximize
transmission and the total virus population being produced (intrahost competition).
We then determine how changes in parameters aﬀect the optimal viral strategy for
transmission and for intrahost competition. While infection of epithelial cells plays a
key role in transmission, intrahost competition emphasizes the role of infection of B
cells. Finally, we apply the results of our within-host model to derive a model of EBV
infection at the population level to study the conditions for invasion and coexistence
of diﬀerent viral strategies.
3.3 Model of the within-host dynamics of
an EBV infection
3.3.1 Model
Our mathematical model (Figure 3.1 and Equation 3.1) describing the dynamics
of EBV infection within an infected host follows two types of target cells (B cells and
epithelial cells), two types of viruses (B-cell-derived, VB, and epithelial-cell-derived,
VE), and two types of cytotoxic T cells or CTLs (attacking latently infected B cells,
T2, and lytically infected cells, T4, respectively). B cells break into four state variables:
naive B cells (B1), latently infected B cells (B2), latently infected memory B cells (B3),
and lytically infected B cells or plasma cells (B4). In B2, there are still 9 latent genes
being expressed and these latently infected cells can be recognized and killed by T cells
(T2). In B3, the virus genome quietly exists inside the cell and is invisible to T cell
responses. Epithelial cells do not ordinarily harbor latent virus and require only two
state variables: uninfected epithelial cells (E1), and lytically infected epithelial cells
(E4). The model consists of a system of 10 ordinary diﬀerential equations,
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Figure 3.1. Model of EBV infection of B cells and epithelial cells. In this model,
we add the infection of epithelial cells to the stages of B-cell infection that have been




= d1(B0 − B1)− μEbVEB1 − μBbVBB1
dB2
dt
= ρ(μEbVEB1 + μBbVBB1)− (d2 + c)B2 − k2B2T2
dB3
dt
= cB2 + rB3 − srB3
dB4
dt
= rB3 − d4B4 − k4B4T4
dE1
dt
= de(E0 − E1)− μBeVBE1 − μEeVEE1
dE4
dt
= μBeVBE1 + μEeVEE1 − (de + γ)E4 − k4E4T4 (3.1)
dVB
dt
= nd4B4 − dvVB
dVE
dt
= nγE4 − dvVE
dT2
dt
= φ2T1w(B2) + θ2T2w(B2)− δT2
dT4
dt
= φ4T1[w(B4 + E4)] + θ4T4[w(B4 + E4)]− δT4 .
The dynamics of B cells obey these assumptions:
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• Naive B cells begin with an initial population of B0 and turn over at rate d1.
They can encounter and be infected by the virus populations VB and VE with
rates μBbVB and μEbVE, respectively.
• An infection of a naive cell, B1, gives rise latently infected cells, B2, by prolifer-
ation of these newly infected cells, where ρ is the proliferation factor. These B2
cells die at a rate d2, can be recognized and killed by eﬀector T cells at a rate
k2T2, and can enter the latently infected memory state at rate c, which is driven
by EBV gene expression switching oﬀ.
• Infected memory cells, B3, obey homeostatic regulation similar to normal memory
B cells. They are invisible to the T cell responses, undergo division with a rate r.
On average, one cell becomes lytically infected and one remains in the memory
state. The rate sr represents the death of B3 due to homeostatic regulation
of memory cells, where s is the regulation factor. For normal homeostasis, s
= 2 balances the proliferation rate of 2r [54]. The frequent turnover of the
memory B cell population helps maintain the supply of plasma B cells that
produce antibodies against various types of antigens. EBV takes advantage of
this mechanism to activate its lytic cycle.
• Lytically infected B cells, B4, arise from lytic reactivation of infected memory
B cells, B3, at rate r, die and release viruses at a rate d4, and can be killed by
eﬀector T cells at a rate k4T4.
The dynamics of epithelial cells assume the following:
• Uninfected epithelial cells start with initial population E0, and turn over at a
rate de. They can encounter and be infected by the virus populations VB and VE
with rates μBeVB and μEeVE, respectively.
• Lytically infected epithelial cells, E4, die naturally at a rate de, die from virus
bursting out at a rate γ, and can be killed by eﬀector T cells at rate k4T4.
Free viruses, VB and VE, are produced from B cells and epithelial cells at rate nd4 and
nγ respectively, where n is the average burst size, and die at rate dv.
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To model the CTL response, we assume that the naive population, T1, is regulated
at a constant level and, upon stimulation by viral antigens, become eﬀector cells against
latent or lytic infection with rate φ2 or φ4, respectively. The activated eﬀector cells, T2
and T4, can proliferate further with rate θ2 and θ4, respectively, upon stimulation by
viral antigens from infected cells. Each type of eﬀector cell dies at rate δ. Activation





where K is the number of infected cells at which activation or proliferation is half
maximal. Tables 3.1 and 3.2 present the parameter values used for simulation and
analysis of the model.
This system of Equation (3.1) has two equilibria. The infection-free equilibrium is
given by
B∗1 = B0 , E
∗
1 = E0 ,
and every other state variable equals zero. If virus replication is suﬃciently eﬃcient,
there is also a persistent equilibrium, where all state variables take on positive values.






















(s− 1)(d2 + c)(de + γ) , (3.3)
of EBV in a naive host [29] that can be found by the next generation matrix [88].
Infections of both B cells and epithelial cells contribute to the basic reproductive ratio
of EBV. If R0 < 1, the infection-free equilibrium is stable and a long term infection
cannot establish within a host. If R0 > 1, the infection-free equilibrium is unstable
and EBV can establish a persistent infection.
The dynamics of infected cells, viruses, and T cell responses for the case when
R0 > 1 are shown in Figure 3.2. The populations of infected cells and viruses peak
during the second week of infection and then resolve down to low levels at equilibrium.
32
Table 3.1. Parameters for the dynamics of B cells (Equation 3.1). We use many
parameters from PathSim, where the rates are estimated and given in a unit of per 6
minutes [78], and convert them into the unit of per minute.
Parameter Description Value Unit Reference
d1 Turnover rate of naive B cells 1/6000 min
−1 [78]
μEb B cell infection rate per 3.3× 10−10 min−1virus−1 [78] 1
epithelial-cell virus
μBb B cell infection rate per μEb/100 min
−1virus−1 [36]
B-cell virus
ρ Proliferation factor 2 no unit [78]
d2 Death rate of latently infected 1/11520 min
−1 [78]
B cells
c Rate of latently infected cells 0.001 min−1 [78] 2
going into memory stage
k2 Rate of latently infected 3.8× 10−8 min−1cell−1 [78] 3
B cells killed by T cells
r Rate of reactivation of lytic 8.3× 10−5 min−1 [78]
infection from latent infection
s Regulation factor of 2 no unit [54]
memory B cells
d4 Death rate of lytically infected 1/4320 min
−1 [78]
cells due to viruses bursting out
k4 Rate of lytically infected 7.6× 10−8 min−1cell−1 [78]3
B cells killed by T cells
1Probability of virus and cell encounter per minute multiplied by the probability of infection and
divided by the number of viruses (≈ 107)
2We take this to be the same rate as the estimation of .1% of lymphocytes leaving
the Waldeyer’s ring per minute
3Probability of lymphocyte encounter per minute multiplied by the probability that Ti kills its
target and divided by the number of Ti(≈ 104)
Infection of epithelial cells plays a larger role during the primary infection than during
the long-term infection. Simulation of EBV infection using the agent-based model,
PathSim, produces clearance of virus and infected-cells in the case of small viral burst
size or inability of EBV to enter latency within memory B cells [78]. Furthermore, EBV
infection also cannot be established within people with X-linked agammaglobulinemia
because they do not have mature B cells. Our model produced similar results; small
virus burst size (small value of n), no latency within memory B cells (c = 0), or no
mature susceptible B cells (B0 = 0) leads to R0 < 1 and virus clearance.
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Table 3.2. Parameters for the dynamics of epithelial cells, virus, and T-cell responses
(Equation 3.1). We use many parameters from PathSim, where the rates are estimated
and given in a unit of per 6 minutes [78], and convert them into the unit of per minute.
Parameter Description Value Unit Reference
de Turn-over rate of epithelial cells 1/6000 min
−1 1
μBe Epithelial cell infection rate 3× 10−11 min−1virus−1 2
per B-cell virus
μEe Epithelial cell infection rate μBe/5 min
−1virus−1 [36]
per epithelial-cell virus
γ Death rate of infected epithelial 1/6000 min−1
cells due to viruses bursting out 3
n Viral burst size 1000 virus·cell−1 [78]
dv Death rate of virus 1/2160 min
−1 [78]
φ2 Rate of T cell activation 1.95× 10−5 min−1 [78]4
against latent infection
φ4 Rate of T cell activation 4.48× 10−5 min−1 [78]4
against lytic infection
θ2 Rate of T cell proliferation 3.25× 10−5 min−1 [78]5
against latent infection
θ4 Rate of T cell proliferation 3.25× 10−5 min−1 [78]5
against lytic infection
K Number of infected cells when 105 cell [45]
T cell activation is half maximal
δ Death rate of T cells 1/156000 min−1 [78]
1Estimated, taken to be the same as d1
2Estimated, taken to be less than μEb [87]
3Estimated, taken to be less than d4 [4]
4Probability of lymphocyte encounter per minute multiplied by the probability of Ti activation
by Bi, where i = 2 or 4
5Probability of lymphocyte encounter per minute multiplied by the frequency of cell division
(every 8-12 hours)
3.3.2 The eﬀects of change in parameter values on transmission,
persistent infection and the dynamics of EBV infection
Changes in the parameter values can alter the transmission eﬃciency, equilibrium
viral loads, and short-term dynamics after initial infection. Transmission, as we have
seen, depends on the amount of viruses produced by epithelial cells. Most EBV-infected
individuals are healthy carriers and can transmit the virus throughout their lifetime.
Although the amount of transmissible epithelial cell viruses varies during the course of
the infection, over the long term, maximizing transmission is equivalent to maximizing
the equilibrium value of epithelial-cell viruses (V ∗E) produced in the long run. A host
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Figure 3.2. Dynamics of infected cells, viruses, and T cell responses using parameter
values in Tables 3.1 and 3.2
can be infected by multiple strains of EBV, at least during primary infection [82].
In the case of a perfectly cross-reacting T cell response (i.e., one epitope of T cells
responds to all strains of EBV) and a single cell type to infect, the principle of compe-
tition exclusion implies that multiple strains cannot coexist within a host [6]. In our
model, there are two types of target cells and this principle does not necessarily apply.
Numerical solutions of our model, however, do not display equilibrium coexistence in
a host. Furthermore, the strain with higher total number of viruses being produced




E) wins out to establish a persistent infection within a
host. Assuming EBV can modify its ability to infect B cells and epithelial cells, we
investigate the optimal strategy the virus would used to maximize transmission or to
maximize viral load in persistent infection.
We ﬁrst develop a model to describe constraints in viral strategies within a host.
We have assume that μEb > μBb and μBe > μEe (Tables 3.1 and 3.2) since VE are
more eﬃcient at infecting B cells and VB are more eﬃcient at infecting epithelial cells
35
[4]. This same study also found that infection eﬃciency varies among EBV strains.
Assuming EBV can modify its ability to infect B cells and epithelial cells, it can only
do so if there is a trade-oﬀ between the ability to infect B cells and epithelial cells
(Figure 3.3(a)). For example, VB can improve its ability to infect B cells by increasing
its expression of gp42. By doing so, however, it decreases its ability to infect epithelial
cells.
To model this tradeoﬀ, we constrain the infection rates to be weighted averages of
the pure VB and VE strategies, which are represented by μB and μE respectively. Let





























The weighted parameters αB and αE deﬁne strategies of VB and VE, respectively. If
αB = 1 and αE = 0 (Figure 3.3(b), upper left), the η’s take on the same values as the
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Figure 3.3. Trade-oﬀ in the ability to infect B cells and epithelial cells. (a) For a
virus, increase in infection of B cells results in decrease in infection of epithelial cells
and vice versa. (b) The strategies of VB and VE are deﬁned as αB and αE, respectively;
as these two parameters increase, both types of viruses prefer to infect epithelial cells.
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αE increases, VE switch from infecting B cells to infecting epithelial cells. When αB
and αE are small, both VB and VE prefer to infect B cells (Figure 3.3(b), bottom left).
In contrast, when αB and αE are large, both VB and VE prefer to infect epithelial cells
(Figure 3.3(b), upper right). At the bottom right corner of Figure 3.3(b), where αB is
small and αE is large, VB prefer to infect B cells and VE prefer to infect epithelial cells.
Replacing μ by η in the system of Equation (3.1), the equilibrium values V ∗E(αi) and
V ∗T (αi) can be found numerically for any given strategy (αB, αE). Our next step is to
analyze the eﬀects of parameters on viral strategies that maximize V ∗E and V
∗
T .
Natural variation between individuals in the expression of EBV receptors (HLA
class II on B cells and CR2 or integrins on epithelial cells) can aﬀect the susceptibility
of these cells to EBV infection [26, 37]. The susceptibility of B cells and epithelial cells
to virus classes VB and VE are described by the parameters μBb, μBe, μEb, and μEe.
We thus focus our sensitivity analysis on these four parameters and the other three
parameters that are related to the production of viruses within a host: the rate of virus
replication and production from B cells (d4) and from epithelial cells (γ), and the viral
burst size (n). We consider each of these parameters at three diﬀerent values: the value
listed in Tables 3.1 and 3.2 (middle), this value divided by two (small) and multiplied
by two (large). For example, the three values for n are 500, 1000, and 2000. We
thus have 37 (or 2187) parameter combinations to study. We ran the same sensitivity
analysis on all other parameters in Table 3.1 and 3.2 but found minimal eﬀects on the
optimal strategy for transmission and establishment of a persistent infection.
3.3.2.1 Identifying strategies that maximize
transmission
We assume that EBV maximizes transmission to new hosts by maximizing equi-
librium amount of virus produced by epithelial cells (V ∗E). We divide the αBαE-plane
in Figure 3.3(b) into 21× 21 grid where each of the 441 points on the grid represents
a viral strategy. For every parameter set, we ﬁnd V ∗E numerically for all strategies
and locate the strategy where V ∗E is maximized. Figure 3.4 shows the inﬂuence of
parameter values on the viral strategy that maximizes V ∗E . We focus our presentation
of the results at the four corners where VB and VE prefer to switch infections between
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Region I: αB ≥ 0.75 and αE ≤ 0.25 

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 Region II: αB ≥ 0.75 and αE ≥ 0.75
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 Region IV: αB ≤ 0.25 and αE ≥ 0.75
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0 αE 1
Figure 3.4. Eﬀects of parameter values on optimal transmission (maximizing V ∗E).
Each parameter takes on three diﬀerent values: small, medium, and large. The
four panels summarize parameter sets that give optimal V ∗E at the four corners in
Figure 3.3(b). Region I: αB ≥ 0.75 and αE ≤ 0.25; Region II: αB ≥ 0.75 and αE ≥ 0.75;
Region III: αB ≤ 0.25 and αE ≤ 0.25; Region IV: αB ≤ 0.25 and αE ≥ 0.75. The dot
size represents the number of times the parameters take on particular values.
the two cell types (Region I), to primarily infect epithelial cells (Region II), to mainly
target B cells (Region III), and to infect their own producing cells (Region IV).
• A minority of parameters (180 out of 2187 sets) favor a strategy similar to what
has been observed in vitro where VB preferentially infect epithelial cells and VE
preferentially infect B cells (Region I) [4]. The parameter sets that maximize V ∗E
in this region tend to have μBe, n, and γ small and μEe and d4 large.
• A large number of parameter sets (1548 out of 2187) favor strategies where both
VB and VE preferentially infect epithelial cells (Region II).
• The remaining parameter sets (459 out of 2187) favor strategies that lie in a
range where αB is large and αE is at an intermediate value.
38
• There are no parameter sets favoring strategies in Region III and IV where αB
is small, implying that B-cell viruses must infect epithelial cells to maximize
transmission.
Figure 3.5 shows the time-course dynamics of free viruses and the T cell responses
for sample sets of parameters from Region I and Region II in Figure 3.4. The viral load
initially elevates, peaks during the second week of infection, and then resolves down to
a low equilibrium level. Strategies in Region II of the αBαE-plane give higher V
∗
E at
the expense of lower V ∗B.
1
Region I: αB ≥ 0.75 and αE ≤ 0.25 
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 Region II: αB ≥ 0.75 and αE ≥ 0.75




















































































































Region III: αB ≤ 0.25 and αE ≤ 0.25 

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Figure 3.5. Eﬀects of parameter values on dynamics of the model for sample sets of
parameters from the two upper corners in Figure 3.4.
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3.3.2.2 Identifying strategies that maximize total viral
load
We now make the assumption that a host gets infected by two or more EBV strains
that diﬀer only in their strategies on the αBαE-plane. In the case of a perfectly cross-
reacting T cell response, our numerical results show that a virus with higher V ∗T would
win out to establish a persistent infection with no stable coexistence of multiple strains
within a host. We thus assume that the intrahost competition will select the virus
that maximizes the total number of virions produced at equilibrium. For each of the
2187 sets of parameters, we found V ∗T numerically and located the strategy where V
∗
T is
maximized. Figure 3.6 shows the inﬂuence of parameter values on viral strategy that
maximizes V ∗T . The optimal strategies lie predominantly in Region III (1449 out of
1
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Figure 3.6. Eﬀects of parameter values on a persistent infection (maximizing V ∗T )
with similar notation as in Figure 3.4.
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2187 sets of parameters), 294 sets in Region II, with only a few conditions favoring a
strategy in Region I (12 sets) or Region IV (33 sets). The remaining parameter sets
(389) favor strategies in the middle and between the four regions.
• In Region II, both VB and VE prefer to infect epithelial cells. The parameters
values for which V ∗T is maximized in this region are characterized by a high rate
of virus production in epithelial cells (γ) and a low rate of virus production in B
cells (d4).
• The majority of parameter values favor strategies in Region III where both VB
and VE prefer to infect B cells. This implies that the infection of B cells plays
a key role in the intrahost competition and the establishment of a long term
infection.
Time-course dynamics of free viruses and the T cell responses for sample sets of
parameters from the four Regions I-IV are shown in Figure 3.7. Higher levels of V ∗E
often come at the expense of lower V ∗B.
3.4 A model of between-host dynamics
For most sets of parameters, maximizing V ∗E for transmission and maximizing V
∗
T for
intrahost competition favor diﬀerent strategies. To predict the outcome of this conﬂict,
we develop an implicit model of EBV dynamics in a homogeneous population of hosts
that includes both transmission and superinfection. This model tracks susceptible
hosts and hosts infected by one of m strains of viruses. We make the assumption that
virus strains do not coexist within a single host. A more competitive virus, with a
higher value of V ∗T , can take over a host from one with a lower value of V
∗
T although
the takeover requires time [1, 58]. We ﬁrst analyze the model for the case where m = 2
and ﬁnd the conditions for coexistence of diﬀerent viral strategies within a population.
We study the case where m > 2 primarily through simulation.





E), is captured by the following system of equations with three state
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Region III: αB ≤ 0.25 and αE ≤ 0.25 


 Region IV: αB ≤ 0.25 and αE ≥ 0.75









































































































Figure 3.7. Eﬀects of parameter values on dynamics of the model for sample sets of
parameters from the four Regions I-IV in Figure 3.6.
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variables: susceptible hosts (S), hosts infected by strain 1 (I1), and hosts infected
by strain 2 (I2).
dS
dt
= σN − μ(α1) I1
N








S − μ(α2)ν(α2, α1) I2
N
I1 + μ(α1)ν(α1, α2)
I1
N






S + μ(α2)ν(α2, α1) I1
I2
N
− μ(α1)ν(α1, α2) I1
N
I2 − σI2 .
This model assumes that
• There is no infection-induced death because mortality due to EBV infection
is very rare even in the case of severe infectious mononucleosis. The total
population, N = S + I1 + I2, is conserved by setting the per capita birth rate
equal to the death rate, σ.
• Susceptible individuals are infected by strain i at rate μ(αi)Ii/N , where μ(αi) =
aV ∗E(αi). This implies that the infection rate of strain i is proportional to the
number of epithelial-cell viruses of that strain being produced within an infected
host.
• Hosts infected by strain i can be superinfected, or taken over, by virus strain j




ν(αj, αi) = g(V
∗
T (αj)− V ∗T (αi))





which is scaled so that g′(0) = 1/A and lim
x→∞
g(x) = 1.
• For all i, the transmission rate is larger than the birth and death rates (μi > σ).
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(N − I1 − I2) + f21 I1
N




T (α2)− V ∗T (α1))− μ(α1)g(V ∗T (α1)− V ∗T (α2))
summarizes the competitive ability of strain 2 relative to strain 1.




T (α1) > V
∗
T (α2), strain 1 is better at both transmis-
sion and intrahost competition and will thus always win. If V ∗E(α1) > V
∗
E(α2) and
V ∗T (α1) < V
∗
T (α2), strain 1 is better at transmission while strain 2 is better at intrahost
competition. Then μ1 = μ(α1) > μ2 = μ(α2) and f21 > 0.
Equation (3.8) has four equilibria:


























Linear stability analysis implies that:
• The disease-free equilibrium, P0, is unstable if μi > σ.
• The strain 1 equilibrium, P1, is positive and stable if f21 < σ(μ1−μ2)(μ1−σ) .
• The coexistence equilibrium, P12, is positive and stable if σ(μ1−μ2)(μ1−σ) < f21 <
σ(μ1−μ2)
(μ2−σ) .
• The strain 2 equilibrium, P2, is positive and stable if f21 > σ(μ1−μ2)(μ2−σ) .
If f21 is small, the force of superinfection is weak and strain 1 wins since it has a
higher transmission rate. As f21 increases, strain 2 can coexist, and will eventually
outcompete strain 1 for larger values of f21.
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where fij = 0 when i = j. Using the assumption of constant population size, Equa-










+ FiIi − σIi . (3.11)
We can think of Fi as the total force of strain i taking over other strains. If V
∗
T (αi) is
small, fij can be negative and, hence, Fi can have a negative value. If V
∗
T (αi) is large,
fij is more likely to be positive and so is Fi. At equilibrium, we have
















Strain i thus can exist at equilibrium if







> σ . (3.12)
The condition for invasion can be expressed in terms of Equation (3.12). Let G be a
set of strains (G ⊂ {1, 2, ..., k}) that can exist in the equilibrium state. Strain i, which
is not in G, can invade the equilibrium if Equation (3.12) is satisﬁed. This implies that
if strain i is not intrahost competitive (low V ∗T (αi) and hence F
∗
i is negative), then it
can only invade the equilibrium if it has a high transmission rate (high V ∗E(αi) and
hence μi).
The force of infection, F ∗i , depends on the scaling factor A (Equation 3.7). When
A is small, |fij| is large and the force of superinfection is strong making it easier for a
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strain with a higher V ∗T to win via intrahost competition (Figure 3.8: row 1, col. 1).
When A is large, the force of superinfection is weaker. It is more diﬃcult for a strain
with higher V ∗T to take over a host from a strain with lower V
∗
T . Instead, strains with
lower V ∗T but higher V
∗
E (higher transmission) can invade and exist in the equilibrium
(Figure 3.8).
The pressure of intrahost competition thus favors strains with small αB and small
αE to maximize V
∗
T . The pressure of transmission, however, supports strains with large
αB and large αE such that V
∗
E is maximized. When the importance of intrahost com-
petition is weak, strategies of higher transmission become dominant and coexistence
of multiple strains is possible at the population level.
3.5 Discussion
We have developed models of the within-host and the between-host dynamics of
EBV infection to study the eﬀects of switching host cell tropism on transmission,
persistence, and viral evolution. The model of the within-host dynamics tracks B
cells, epithelial cells, T cells, and viruses. Although our model does not explicitly
include spatial dynamics, the numerical solution of the dynamics of B cell infection
(Figure 3.2) are consistent with simulations of the agent-based model, PathSim, such
that small virus burst size or exclusion of a memory stage produces clearance [78]. This
result supports the key role of virus latency within memory B cells in the establishment
of a persistent EBV infection within a host. The agent-based models, however, did not
address the importance of epithelial cell infection.
Viruses derived from B cells (VB) preferentially infect epithelial cells and viruses
derived from epithelial cells (VE) preferentially infect B cells [4]. Viruses derived
from epithelial cells are the main type that is shed in saliva, and play a key role
in transmission [44]. Assuming EBV can modify its ability to infect B cells and
epithelial cells, we compute viral strategies that maximize transmission and persistent
infection. Maximizing transmission is assumed to be equivalent to maximizing the
equilibrium amount of virus produced from epithelial cells. Maximizing intrahost

















































































































































Figure 3.8. Snapshots of winning and coexisting strains with the corresponding density
of infected hosts at equilibrium (red ‘*’) as A increases (|fij | decreases) for a sample set of
parameter from Region III in Figure 3.6. We consider 441 strains (blue ‘*’ ) representing
diﬀerent viral strategies on the αBαE plane.
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viruses at equilibrium. Under most conditions, the optimal strategy for transmission
is having both types of viruses (VB and VE) to preferentially infect epithelial cells.
Under conditions when the rate of virus replication and production from B cells is
high and production from epithelial cells is low, maximizing transmission favors viral
strains that have viruses produced by one cell type infecting the other, in accord
with observations of viral behavior in vitro [4]. In contrast, the optimal strategy for
establishing and maintaining a persistent infection (intrahost competition) is for both
types of viruses to mainly infect B cells, an observation consistent with reports that, at
least in healthy carriers, EBV primarily targets and maintains its persistent infection
within the population of B cells [33].
For the majority of parameter combinations we studied, maximizing V ∗E for trans-
mission and maximizing V ∗T for intrahost competition favor diﬀerent strategies. No
stable coexistence of multiple strategies is observed within a host. This may be due to
the assumption of perfect cross-reactivity of T cells in our model. To further understand
the conﬂict of strategies, we combine these results of the within-host model with a
model at the population level and show that coexistence is possible. This between-host
model includes both transmission and superinfection. In this case, when the force of
superinfection is strong, viruses that preferentially infect B cells survive within and
between hosts. When the importance of intrahost competition is weak, strategies of
higher transmission become dominant and coexistence of multiple strains is possible at
the population level.
Multiple strains of EBV, indeed, have been detected within healthy carriers for
periods of more than 300 days [82]. There are at least two possible explanations for
this. If multiple strains coexist at the host population level, as in our model, but
within-host takeovers are slow, individuals could have transient multiple infections.
Alternatively, coexistence of multiple strains within a host could result from either
partial or no cross-reactivity of T cell responses. Our model can be modiﬁed to allow
for either of these complications.
The existence of multiple strains, T cell responses, and the switching of infection
between cell types may not only play important roles in the evolution of EBV but
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also in the pathology of EBV-associated diseases like infectious mononucleosis and
nasopharyngeal carcinoma. Infectious mononucleosis (IM) is thought to be caused by
primary infection of EBV in teenagers and young adults with symptoms including
fever, fatigue, and sore throat. The overwhelming number of T cells, especially against
viral lytic proteins cause these symptoms [33]. With the existence of multiple strains,
it is possible that IM may be caused by a secondary infection with a strain that is
particularly eﬃcient at lytic replication and production of new viruses. For example,
an infection with a strain that is highly eﬃcient at infecting epithelial cells may generate
an extreme T cell response against EBV lytic proteins and cause symptoms of IM.
Nasopharyngeal carcinoma is a cancer of epithelial cells in the nose and pharynx.
EBV infection of epithelial cells normally results in lytic infection. In NPC patients,
however, EBV can maintain latency within epithelial cells. Expression of virus latent
proteins within these cells contributes to cell proliferation, cell survival, and ineﬃcient
T cell responses, all of which can accelerate tumor development. The shift of tropism
from B cell to epithelial cell disease may be induced by immunoglobulin A (IgA)
[83], which can enhance the viral entry into epithelial cells while interfering with the
infection of B cells. Ongoing research extends the basic model of within-host dynamics
(Equation 3.1) to study the association of EBV infection with these two important
pathologies, IM and NPC.
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CHAPTER 4





Most people get Epstein-Barr virus (EBV) infection at young age and are asymp-
tomatic. Primary EBV infection in adolescents and young adults however, often leads
to infectious mononucleosis (IM) with symptoms including fever, fatigue, and sore
throat that can persist for months. Expansion in the number of CD8+ T cells, especially
against EBV lytic proteins, are the main cause of these symptoms. We propose a
mathematical model for the regulation of EBV infection within a host to address the
dependence of IM on age. This model tracks the number of virus, infected B cell
and epithelial cell, and CD8+ T-cell responses to the infection. We use this model
to investigate three hypotheses for the high incidence of IM in teenagers and young
adults: saliva and antibody eﬀects that increase with age, high cross-reactive T-cell
responses, and a high initial viral load. The model supports the ﬁrst two of these
hypotheses, and suggests that variation in host antibody responses and the complexity
of the pre-existing cross-reactive T cell repertoire, both of which depend on age, may
play important roles in the etiology of IM.
4.2 Introduction
EBV is transmitted by intimate contact, mainly through saliva and oropharyngeal
secretion [3]. Within a host, the virus primarily targets two cell types, B cells and
epithelial cells. Host saliva and antibodies, like IgA and IgG, to viral glycoproteins can
decrease the infection of B cells but enhance the infection of epithelial cells [83, 87].
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Most people get EBV infection at young age and are asymptomatic. Adolescents and
young adults infected with EBV develop infectious mononucleosis in up to 50% of
cases, with symptoms including fever, fatigue, and sore throat that can persist for
months [3, 15]. These symptoms are caused mainly by expansion in the number of
CD8+ T cells, especially against EBV lytic proteins expressed during lytic replication
and production of virions [33].
In the previous chapter (Chapter 3), we developed a mathematical model of the
within-host dynamics to study EBV long term infection and viral evolution. In this
chapter, we extend the within-host model to include features of immune system thought
to be important in IM: the role of antibodies in shifting infections between the two cell
types and the eﬀect of speciﬁc and cross-reactive T-cell responses. The model tracks
the number of viruses, infected B cells and epithelial cells, speciﬁc CD8+ T cells, and
cross-reactive CD8+ T cells responding to the infection.
We use this model to investigate the following three hypotheses.
• Saliva and antibody eﬀects
Host saliva and antibodies to EBV proteins promote infection of epithelial cells
which, in turn, can induce an elevated CD8+ T-cell response against lytic infec-
tion. This hypothesis comes from observations that some unknown factor in host
saliva and antibodies to viral proteins have been observed to enhance epithelial
cell infection, and that salivary IgA level increases with age [42, 83, 87, 91].
• Cross-reactive T-cell responses
The complexity of the pre-existing memory T-cell repertoire may change with
age. Adolescents infected with EBV may recruit large numbers of cross-reactive
memory T cells previously created in response to other viral infections. These
cross-reactive T-cell responses may be more quickly activated, but less eﬃcient
in controlling the infection than primary responses from naive T cells [14, 73].
• The initial viral load
High viral challenges in adolescents, often acquired via kissing, may induce ag-
gressive CD8+ T-cell response [33].
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4.3 Model
Addressing the three hypotheses for the causes of IM requires consideration of
antibody eﬀects and state variables representing cross-reactive T-cell responses to
latent and lytic infection. Our mathematical model (Figure 4.1 and Equation 4.1)
tracks two types of target cells, B cells and epithelial cells, both B-cell derived (VB)
and epithelial-cell derived (VE) viruses, two types of speciﬁc cytotoxic T cells (CTLs)
attacking latently infected B cells (T2) and lytically infected cells (T4), respectively,
and two types of cross-reacting CTLs against latently (T2c) and lytically (T4c) infected
cells. B cells is classiﬁed further into four state variables: naive B cells (B1), latently
infected B cells (B2), latently infected memory B cells (B3), and lytically infected B
cells or plasma cells (B4). Epithelial cells do not ordinarily harbor latent infection and

























V E + IgA 
T4c T4c 
Epithelial Cell 
Figure 4.1. Model of EBV infection of B cells and epithelial cells. Antibodies like IgA
can shift the viral target from B cells to epithelial cells. Activation of cross-reactive
memory T cells (TC) that are not eﬃcient in killing infected cells may contribute to
the pathology of IM.
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= d1(B0 − B1)− f(a)μEbVEB1 − f(a)μBbVBB1
dB2
dt
= ρ(f(a)μEbVEB1 + f(a)μBbVBB1)− (d2 + c)B2 − k2B2T2 − χ2k2B2T2c
dB3
dt
= cB2 + rB3 − srB3
dB4
dt
= rB3 − d4B4 − k4B4T4 − χ4k4B4T4c
dE1
dt
= de(E0 − E1)− h(a)μBeVBE1 − h(a)μEeVEE1
dE4
dt
= h(a)μBeVBE1 + h(a)μEeVEE1 − (de + γ)E4 − k4E4T4 − χ4k4E4T4c (4.1)
dVB
dt
= nd4B4 − dvVB
dVE
dt
= nγE4 − dvVE
dT2
dt






= (1− σ4)φ4TN [w(B4 + E4)] + θ4T4[w(B4 + E4)]− δT4
dT4c
dt
= σ4mφ4TM [w(B4 + E4)] +mθ4T4c[w(B4 + E4)]−mδT4c .
The dynamics of B cells obey these assumptions:
• Naive B cells have an initial population size of B0 and turnover rate d1. They
encounter and are infected by VB and VE with rates f(a)VBμBb and f(a)VEμEb,
respectively, where f(a) represents the inhibiting eﬀect of host saliva and anti-
body responses on infection of B cells (Equation 4.3).
• An infection of a naive cell, B1, may give rise to one or more latently infected
cells, B2, due to the limited proliferation of these newly infected cells, where ρ
is the proliferation factor. These B2 cells die at rate d2, and are recognized and
killed by speciﬁc or cross-reactive eﬀector T cells at rate k2 or χ2k2, respectively.
They can also enter the latently infected memory state, driven by EBV turning
oﬀ its gene expression, at rate c.
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• Infected memory cells, B3, obey homeostatic regulation similar to normal memory
B cells. They are invisible to the immune system, and undergo cell division with
rate r, where one cell goes into lytic infection and one stays in the memory state.
The rate sr represents the death of B3 due to homeostasic regulation of memory
cells, where s is the regulation factor. For a normal homeostasis, s = 2 balances
the proliferation rate of 2r [54].
• Lytically infected B cells, B4, arise from lytic reactivation of memory infected B
cells at rate r, die and release viruses at rate d4, and can be killed by speciﬁc or
cross-reactive eﬀector T cells at rate k4 or χ4k4, respectively.
Here, χj (j = 2 or 4), with 0 ≤ χj ≤ 1, characterizes the eﬃciency of cross-reactive T
cells in killing infected cells, compared to speciﬁc T cells. The smaller χj is, the more
ineﬃcient cross-reactive T cells are in killing infected cells.
The dynamics of epithelial cells assume the following:
• Uninfected epithelial cells have initial population size of E0 with turnover rate
de. They encounter and are infected by VB and VE with rates h(a)VBμBe and
h(a)VEμEe, respectively. Here, h(a) represents the enhancement eﬀect of host
saliva and antibody responses on infection of epithelial cells (Equation 4.4).
• Lytically infected epithelial cells, E4, die at natural rate de, die due to virus
bursting out at rate γ, and can be killed by speciﬁc or cross-reactive eﬀector T
cells at rate k4 or χ4k4, respectively.
The eﬀects of host saliva and antibody responses on the infection of the two cell
types are represented by the functions f and h, and included as parameters in the
cell-speciﬁc infection terms. This is based on the observation that host saliva and
antibodies to viral glycoproteins interfere with infection of B cells and enhance infection
of epithelial cells [87]. From limited data in this in vitro study, we obtain the linear
relationship between f and h that can be described in the following equation:
h = 1 + λ− λf , (4.2)
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where λ ≈ 32. The functions f and h carry no units. Without the antibody eﬀect,
f = 1 and h = 1. With antibody eﬀects, f decreases to represent decreased eﬃciency
in infection of B cells and h increases to represent increased eﬃciency in infection of
epithelial cells. To model the dependence of f and h on antibody response, we assume
that the two functions take on the forms








where a represents the strength of saliva and antibody eﬀects. We will refer to a
as the antibody eﬀect from now on because the factor(s) in saliva that can enhance
infection of epithelial cells remain unknown. The functions f(a) and h(a) take the
form of Hill functions, where λ is the maximum level of the antibody eﬀect on the
infection of epithelial cells and A is the level of a where the eﬀect on the infection
of B cells and epithelial cells is half maximal. As a increases, f(a) decreases while
h(a) increases before saturating. This saturating form assumes that a certain level of
antibody response is required to have strong eﬀects on the infection of both cell types.
Free viruses, VB and VE, are produced from B cells and epithelial cells at rates nd4
and nγ, respectively, where n is the average burst size. These viruses die at rate dv.
To model the CTL response, we separate the speciﬁc responses against latent (T2) and
lytic (T4) infection coming from naive T cells and the cross-reactive responses (T2c and
T4c) coming from the memory T cells speciﬁc to other encountered pathogens.
We assume that the naive and memory populations, TN and TM , are ﬁxed at
constant levels. Upon stimulation by viral antigens, TN become eﬀector cells against
latent or lytic infection at rate (1 − σ2)φ2 or (1 − σ4)φ4, respectively, where σj is the
fraction of cross-reactive T-cell response. With further stimulation by viral antigens
from infected cells, the activated eﬀector cells, T2 and T4, can proliferate with rates θ2
and θ4, respectively. Each type of eﬀector cell dies at a similar rate δ. Activation and






where K is the number of infected cells at which activation or proliferation is half
maximal and is assumed to be the same for both responses.
Cross-reactive responses, T2c and T4c, are activated from the memory population
at rate σjmφj, where m ≥ 1 is a measurement of how much faster a response can
be activated from memory T cells compared to activation from naive T cells. These
cross-reactive memory cells are assumed to have faster dynamics than speciﬁc T cells.
Although they may be activated quickly and proliferate rapidly, they die faster (by a
factor m). This comes from observations that memory cells respond with fast kinetics
[46], but are also more susceptible to death [10]. Furthermore, T cells obtained from
acute IM patients have been shown to have high expression of programmed-death-1
[33].
The system Equation (4.1) has two equilibria: an infection-free equilibrium and a
persistent equilibrium. The infection-free equilibrium is given by
B∗1 = B0 , E
∗
1 = E0 ,
with other state variables equal zero. The stability of the infection-free equilibrium is





















(s− 1)(d2 + c)(de + γ) . (4.6)
Infections of both B cells and epithelial cells contribute to the basic reproductive ratio
of EBV. The antibody eﬀects, f(a) and h(a), shift the weight of R0 contribution from
B cells to epithelial cells. If R0 < 1, the infection-free equilibrium is stable and the
infection cannot establish within a host. If R0 > 1, the infection-free equilibrium is
unstable and EBV can establish a persistent infection, where all state variables take on
positive values. Tables 4.1 and 4.2 present the parameter values used for simulations
and analysis of the model.
Assuming no cross-reactive responses (σ2, σ4 = 0), the dynamics of viruses and T
cells for the cases without antibody eﬀect (a = 0) and with antibody eﬀect (a = 10) are
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Table 4.1. Parameters for the dynamics of B cells and antibody eﬀect used in the
model simulations (Equation 4.1). We use many parameters from PathSim, where the
rates are estimated and given in a unit of per 6 minutes [78], and convert them into
the unit of per minute.
Parameter Description Value Value Reference
d1 Turnover rate of naive B cells 1/6000 min
−1 [78]
μEb B cell infection rate per 3.3× 10−10 min−1virus−1 [78] 1
epithelial-cell virus
μBb B cell infection rate per μEb/100 min
−1virus−1 [36]
B-cell virus
ρ Proliferation factor 2 no unit [78]
d2 Death rate of latently infected 1/11520 min
−1 [78]
B cells
c Rate of latently infected cells 0.001 min−1 [78] 2
going into memory stage
k2 Rate of latently infected 3.8× 10−8 min−1cell−1 [78] 3
B cells killed by T cells
r Rate of reactivation of lytic 8.3× 10−5 min−1 [78]
infection from latent infection
s Regulation factor of 2 no unit [54]
memory B cells
d4 Death rate of lytically infected 1/4320 min
−1 [78]
cells due to viruses bursting out
k4 Rate of lytically infected 7.6× 10−8 min−1cell−1 [78]3
B cells killed by T cells
a The strength of antibody eﬀect variable (0-40) no unit
A Level of a where antibody eﬀect 10 no unit
is half maximal
λ Maximal level of antibody eﬀect 32 no unit [87]4
on epithelial cell infection
1Probability of virus and cell encounter per minute multiplied by probability of infection and
divided by the number of viruses (≈ 107)
2We take this to be the same rate as the estimation of .1% of lymphocytes leaving
the Waldeyer’s ring per minute
3Probability of lymphocyte encounter per minute multiplied by the probability that Ti kills its
target and divided by the number of Ti(≈ 104)
4Estimated from limited data given in an in vitro study [4]
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Table 4.2. Parameters for the dynamics of epithelial cells, virus, and T-cell responses
used in the model simulations (Equation 4.1).
Parameter Description Value Unit Reference
de Turn-over rate of epithelial cells 1/6000 min
−1 1
μBe Epithelial cell infection rate 3× 10−11 min−1virus−1 2
per B-cell virus
μEe Epithelial cell infection rate μBe/5 min
−1virus−1 [36]
per epithelial-cell virus
γ Death rate of infected epithelial 1/6000 min−1
cells due to viruses bursting out 3
n Viral burst size 1000 virus·cell−1 [78]
dv Death rate of virus 1/2160 min
−1 [78]
σj Fraction of eﬀector cells activated variable (0-1) no unit
from cross-reactive memory T cells
m Factor of faster response 5 no unit [46]
from memory T cells
φ2 Rate of T cell activation 1.95× 10−5 min−1 [78]4
against latent infection
φ4 Rate of T cell activation 4.48× 10−5 min−1 [78]4
against lytic infection
θ2 Rate of T cell proliferation 3.25× 10−5 min−1 [78]5
against latent infection
θ4 Rate of T cell proliferation 3.25× 10−5 min−1 [78]5
against lytic infection
K Number of infected cells when 105 cell [45]
T cell activation is half maximal
δ Death rate of T cells 1/156000 min−1 [78]
1Estimated, taken to be the same as d1
2Estimated, taken to be less than μEb [87]
3Estimated, taken to be less than d4 [4]
4Probability of lymphocyte encounter per minute multiplied by the probability of Ti activation
by Bi, where i = 2 or 4
5Probability of lymphocyte encounter per minute multiplied by the frequency of cell division
(every 8-12 hours)
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shown in Figure 4.2(i) and 4.2(ii), respectively. The antibody eﬀect greatly increases
the number of viruses being produced, with most of this increase coming from epithelial-
cell viruses. Elevated number of T cells against viral lytic proteins are induced during
primary infection.
4.4 Application to infectious mononucleosis
EBV infection in children of young age is usually asymptomatic. Adolescents
and young adults infected with EBV may develop ﬂu-like symptoms, referred to as
infectious mononucleosis (IM). These symptoms result from a massive T-cell response
to EBV a few weeks after the initial viral infection that can last from a few weeks to
several months [15]. The T-cell responses against viral latent proteins are generally
(i) (ii)
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Figure 4.2. Dynamics of viruses and T cells in the case of no cross-reactive T-cell
responses (σj = 0). (i) Without antibody eﬀect (a = 0). (ii) With antibody eﬀect
(a = 10). The insets show the level of persistent virus for the two cases. Parameter
values used are shown in Tables 4.1 and 4.2.
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smaller in magnitude than the T-cell responses against viral lytic proteins during the
acute phase of IM. The acute phase is followed by convalescence and eventually a virus
carrier state where the CD8+ population resolves to a level comparable to that in
asymptomatic carriers [33].
We use numerical solutions of our model to investigate the three hypotheses for
the high prevalence of IM in teenagers and young adults: saliva and antibody eﬀects,
cross-reactive T-cell responses, and the initial viral load. The total number of T cells
(both speciﬁc and cross-reactive ones) and the lytic T cell ratio at the peak of infection
are used as the two key measurements of IM. The lytic T cell ratio is the ratio between
eﬀector T cells responding against lytic infection and eﬀector T cells responding against
latent infection, (T4+T4C)/(T2+T2C). A wide range of values of these two measurements
has been observed in IM patients. Individual epitope responses against latent and lytic
infections can account for 0.1%-5% and 1%-40% of the total CD8+ T cell population,
respectively [33].
4.4.1 Antibody eﬀects
Race, sex, and age are at least in part responsible for individual diﬀerences in
antibody responses [7, 13, 42], which may inﬂuence the outcomes of EBV infection.
Titers of antibody responses speciﬁc to EBV viral capsid antigen, IgA and IgG, have
been observed to increase with age and IgA attains its highest level during the onset
of disease within IM patients [21, 67]. Furthermore, individuals are exposed to more
pathogens as they age. EBV infection in young adults may activate antibody responses
that are speciﬁc to other viruses, but cross-reactive to EBV. As IgG and IgA responses
to EBV glycoproteins can enhance the lytic infection of epithelial cells, the probability
of getting IM may increase with age.
To examine this hypothesis with our model, we vary the strength of the antibody
eﬀect (a) and study its inﬂuence on the total number of T cells and the lytic T cell ratio
(Figure 4.3) measured at the peak of infection. The total number of T cells increases
with the level of a, but then decreases when a is large. At high levels of antibody
response, infection of B cells is strongly suppressed while the eﬀect on enhancement
of lytic infection of epithelial cells saturates, leading to a decreased total number of T
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Figure 4.3. Antibody eﬀects on the total number of T cells (T2 + T2c + T4 + T4c) and
the lytic T cell ratio ((T4 + T4c)/(T2 + T2c)) in the absence of cross-reactive T cells
(σj = 0). (i) Total number of CD8
+ T cells at the peak of infection. (ii) The lytic T
cell ratio at peak: ratio between the number of T cells against lytic infection (T4) and
the number of T cells against latent infection (T2), evaluated at the peak of infection.
Parameter values are shown in Tables 4.1, and 4.2.
cells (Figure 4.3(i)) and increased lytic T cell ratio (Figure 4.3(ii)).
4.4.2 Cross-reactive T-cell responses
Massive expansion of CD8+ T cells responding to EBV causes the symptoms of
IM [80]. It has been proposed that the high susceptibility of teenagers and young
adults to IM may be due to a more complex memory CD8 repertoire than in young
children. As individuals age, the memory CD8 repertoire gets more complex due to
exposure to diﬀerent pathogens. Adolescents infected with EBV may recruit a large
number of cross-reactive memory T cells previously created in response to other viral
infections [73]. In fact, it has been shown that memory CD8+ T cells speciﬁc to
inﬂuenza virus can be activated and respond to stimulation by EBV lytic proteins [14].
Both the magnitude and the eﬃciency of cross-reactive T cells in killing infected cells
may contribute to the etiology of IM. The level of cross-reactive memory T cell can
increase with age. These memory cells may be faster at activation and proliferation
compared to naive T cells [89], but less eﬃcient in controlling the infection [85].
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A large fraction of CD8+ T cells created during the course of IM respond to lytic
infection (5-50%, compared to 1-3% for T cells responding to latent infection) [8, 32].
Since EBV has many more lytic genes than latent genes [75], it is likely that there are
more cross-reactive T cells to EBV lytic infection than to latent infection. We ﬁrst
assume cross-reaction of only T-cell responses against lytic infection. To address this
assumption with our model, we set σ2 = 0 and consider ﬁve diﬀerent values of σ4, 0,
0.3, 0.6, 0.8, and 1. As σ4 increases, the fraction of lytic T-cell response coming from
cross-reactive memory T cells increases. At σ4 = 1, there is no speciﬁc lytic T-cell
response; all lytic T cells are cross-reactive.
To facilitate comparison with the antibody eﬀect (Figure 4.3), we present the eﬀects
of cross-reactive T cells on the development of IM using similar plots, with ﬁve curves
in each representing diﬀerent values of the level of cross-reactive lytic T cells (σ4)
(Figure 4.4). This ﬁgure also illustrates the impact of χ4, the eﬃciency of cross-reactive
T cells in killing lytically infected cells, on the two measurements of IM. Across all levels
of antibody eﬀects (a), the increase in σ4 greatly elevates the total number of T cells
and the lytic T cell ratio. This eﬀect, however, diminishes as χ4 increases. At χ4 = 1,
cross-reactive lytic T cells are as eﬃcient as speciﬁc T cells in killing infected cells.
In fact, due to their faster response, cross-reactive T cells reduce the overall T-cell
responses and the probability of IM.
We now add the possibility of cross-reactive T-cell responses against latent infection.
Figure 4.5 shows the eﬀects of this addition on the two measurements of IM. For each
level of σ4, we set σ2 = 0.2σ4, to assume lower levels of cross-reactive T cells against
latent infection, compared to lytic infection. We analyzed and observed only minimal
impacts of variation in the eﬃciency of cross-reactive T cells in killing latently infected
cells (χ2), on the results. We thus, ﬁx χ2 = 0.5 for this analysis. In comparison to the
results presented in Figure 4.4(i), addition of cross-reactive T cells to latent infection
does not induce visible eﬀect on the total number of T cells while the lytic T cell ratios
are signiﬁcantly reduced. This implies that cross-reactive T-cell responses to latent
infection do not induce the high lytic ratio observed in IM patients.
62
(i) (ii)





















































strength of antibody effect (a)
























































strength of antibody effect (a)
Figure 4.4. The eﬀects of cross reactive T-cell responses to viral lytic proteins (σ4 > 0)
on the total number of T cells and the lytic T cell ratio during primary infection as
a function of the strength of the antibody eﬀect (a). The ﬁve diﬀerent degrees of
cross-reactive responses are shown in each plot. (i) Left column: low eﬃciency of
cross-reactive lytic T cells in killing infected cells (χ4 = 0.1). (ii) Right column:
cross-reactive T cells are as eﬃcient as speciﬁc T cells in killing infected cells (χ4 = 1).
Other parameter values are shown in Tables 4.1, and 4.2.
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strength of antibody effect (a)
Figure 4.5. The eﬀects of both latent and lytic cross reactive T cells (σj > 0) on the
total number of T cells and the lytic T cell ratio during primary infection as a function
of the strength of the antibody eﬀect (a). The ﬁve diﬀerent degrees of cross-reactive
responses are shown in the plots. For each level of σ4, σ2 = 0.2σ4. We set χ2 = 0.5
and χ4 = 0.1. Other parameter values are shown in Tables 4.1, and 4.2.
4.4.3 High initial viral load
A third hypothesis suggests that transmission often occurs through kissing in adoles-
cents which may transmit a large number of viruses and hence lead to aggressive CD8+
T-cell responses. To analyze this hypothesis, we numerically solve Equation (4.1)
with ﬁve diﬀerent levels of the initial viral load, V0. In comparison to antibody and
cross-reactive T-cell eﬀects, the initial viral load has very little eﬀect on either the total
number of T cells or the lytic T cell ratio (Figure 4.6).
4.4.4 Combined eﬀects of antibody and cross-reactive
T-cell responses
So far, our model supports the roles of antibody eﬀects and the cross-reactive T
cells in the development of IM. To summarize our analysis of the two hypotheses, we
deﬁne two new ratios. The relative lytic T cell ratio gives the lytic T cell ratio for






























































strength of antibody effect (a)
Figure 4.6. The eﬀect of initial viral load (V0) on the total number of T cells and the
lytic T cell ratio during primary infection as a function of the strength of the antibody
eﬀect (a). We set σj = 0, which represents no cross-reactive T cell response. Other
parameter values are shown in Tables 4.1, and 4.2.
The relative total T cell number gives the ratio between the total number of T cells
given values of σj and a and the one with a baseline σj = 0 and a = 0,
(T2 + T4 + T2C + T4C)
(T2 + T4 + T2C + T4C)σj=0,a=0
.
We examine ﬁve diﬀerent levels of cross-reactive T cells to lytic infection (σ4), four
diﬀerent levels of cross-reactive T cell against latent infection (σ2), ﬁve diﬀerent levels
of the eﬃciency of lytic T cells in killing infected cells (χ4), and ﬁx χ2 = 0.5 (Figure 4.7).
Infectious mononucleosis (IM) is assumed to be possible when both ratios, the
relative total T cell number and the relative lytic T cell ratio are large (≥ 5). Studies
give a wide range for these ratios [8, 32, 80], so these threshold levels of ≥ 5 are not
to be conclusive. In the absence of antibody eﬀects (a = 0), IM can only be explained
with very high levels of cross-reactive lytic T cells together with a low eﬃciency of
these cells in killing infected cells. In the absence of cross-reactive T cells (σj = 0,
a > 0), antibody eﬀects induce increases in the total number of T cells and the lytic
T cell ratio. However, these increases are not as signiﬁcant as those induced by the
combined eﬀects of antibodies with cross-reactive T cells. Thus, IM is characterized by
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σ4 = 0.3, 0.6, 0.8, 1; σ2 = 0
 
 
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n a:: σj = 0, a = 0
Figure 4.7. Combined eﬀects of antibodies with cross-reactive T cells on the relative
T cell number and the relative lytic T cell ratio. (i) a = 0. (ii) a = 4. (iii) a = 10.
(iv) a = 30. The green lines show the area of possible IM cases with high levels of the
relative total T cell number and the relative lytic T cell ratio (≥ 5). Four diﬀerent
colors (symbols) represents diﬀerent levels of cross-reactive latent T cells (σ2). Symbol
size represents diﬀerent levels of cross-reactive lytic T cells (σ4 = 0.3, 0.6, 0.8, 1). The
label numbers next to the symbol represent the eﬃciency of lytic T cells in killing
infected cells (χ4). We examine ﬁve diﬀerent levels of χ4 (0.1, 0.2, 0.5, 0.7, 1) and only
label the points of possible IM cases. The characters n and a represent the normal
condition (σj = 0, a = 0) and the conditions with only antibody eﬀects (σj = 0, a > 0),
respectively.
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high level of antibody eﬀects, high level of cross-reactive T cells to lytic infection, and
low eﬃciency of cross-reactive T cell in killing infected cells. As individuals age, the
levels of antibody eﬀects and the cross-reactive T cells increase; hence, the probability
of IM increases if the cross-reactive T cells do not eﬃciently kill infected cells.
4.5 Discussion
Infectious mononucleosis (IM) is characterized by a large T-cell response, primarily
to the lytic phase of the infection and thus can result from two broad changes in
the course of acute infection. First, the virus could be biased towards creating a large
fraction of lytically infected cells. EBV alternates between infecting B cells (its primary
target), with either latent or lytic infection, and epithelial cells (important in viral
persistence and shedding), as lytic infection only. Any factor that biasses infection
toward epithelial cells can increase the importance of lytic infection and potentially
increase the probability of IM. Switching between B-cell and epithelial-cell virus is
modulated by antibody responses and unknown constituents in the saliva [87]. Hosts
with increased IgA antibodies may be prone to large expansions of T cell against viral
lytic proteins. Second, a host could have a less eﬃcient T-cell response against the
virus. EBV infection can activate cross-reactive memory T cells that are speciﬁc to
other pathogens [14]. If these cells are activated in large number, but recognize and
kill target cells ineﬃciently, IM may result. The high initial viral load hypothesis
cannot produce large expansions of T cells and thus cannot be used to explain the age
dependence of IM.
In economically developed countries, IM has highest incidence in the 15- to 25-
year-old age group. In developing countries like Brazil, the age distribution of IM is
shifted downward with mean age of IM around 13 years [62]. If people in developing
countries are exposed to more diseases at an earlier age, they could have both higher
antibody level and a larger pre-existing memory CD8 repertoire compared to age
matched counterparts from developed countries. Together, these eﬀects may explain
the diﬀerence in age distribution of IM.
We built the component of antibody eﬀects in our model based on an in vitro study
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of the host saliva and antibody eﬀects on the infections of B cells and epithelial cells
with limited data from saliva samples of infected and uninfected individuals [87]. The
goal of our study was not to predict the exact level of antibodies that induces large
expansion of T cells and symptoms of IM, but to identify the potential risks in their
eﬀects. Our model highlights a need for further studies on the constituents of the
saliva inﬂuencing infection of the two cell types, and studies to compare the levels
of antibodies, especially IgA, to EBV viral capsid antigens and glycoproteins during
the acute phase of infection between asymptomatic and symptomatic patients. These
studies would help to identify the existence of thresholds of antibody levels or other
factors in the host saliva that direct the course of infection.
We have used our model to show that both the magnitude and the quality of
T cells in killing the infected cells are critical determinants of the outcomes of the
infection. Indeed, our result suggests that large expansion of CD8+ T cells occur
only when they are ineﬃcient at killing. A study on mice shown that infection with
lymphocytic choriomeningitis virus (LCMV), Pichinde virus (PV), or vaccinia virus
(VV) can activate cross-reactive T cells that are speciﬁc to one of these viruses [77].
These cross-reactive responses are fast, functionally eﬃcient, and hence help to clear
the secondary virus infection. Study of T-cell responses to dengue virus has shown that
diﬀerent cross-reactive T cell clones can have very diﬀerent eﬃciencies in recognizing
and killing the infected cells [40]. In vitro study has shown that EBV antigen can
activate cross-reactive T cells that are speciﬁc to inﬂuenza-A virus, but the killing
eﬃciency of these cells has not yet been determined [14]. As the pre-existing memory
CD8 repertoire evolves with age, we do not know how the functional eﬃciency of these
memory cells changes. Further studies to compare the recognizing and killing eﬃciency
of eﬀector T cells during primary infection of EBV between diﬀerent age groups, and
between healthy and IM patients, are needed to address this question and to validate
the results of our model.
Studies have also suggested that genetic factors can contribute to diﬀerences in
eﬃciency of T-cell responses to EBV, which implies diﬀerence in susceptibility to IM
between individuals [56]. Individuals with certain HLA class I alleles are linked to
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higher risk of IM. HLA class I plays a key role in the process of antigen presentation
by infected cells to T cells [23]. Hence, a diﬀerence in HLA alleles can induce diﬀerent
rates at which T cells can be activated, proliferate, recognize, and kill infected cells.
Similar to the way we model the cross-reactive T-cell responses, we can utilize our
model to address this hypothesis on the genetic predisposition to IM.
Even though infectious mononucleosis is rarely lethal, it may induce long-term
eﬀects on the population of T cells [76, 33]. Infectious mononucleosis is strongly
correlated with increased risk of EBV-positive Hodgkin’s lymphoma in the years after
infection [34]. Understanding risk factors for IM may help to investigate the long-term
eﬀects of the disease and its association with more serious disease like cancers.
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CHAPTER 5






Nasopharyngeal carcinoma (NPC) is a cancer of epithelial cells in the nose and
pharynx that has distinct patterns of incidence in diﬀerent populations and geographic
locations. The highest incidence is found in the populations of southern China, South-
east Asia, and Mediterranean Africa, and in Eskimos of the Arctic region, while it is
much lower in the populations of North America and Europe. The undiﬀerentiated
type III is most common and strongly linked with Epstein-Barr virus (EBV) infection
where all tumor samples contain EBV DNA. Latent EBV infection within epithelial
cells in the pharynx, genetic factors, and diet play key roles in the pathogenesis of
NPC. Tumors are found to represent the clonal expansion of an EBV latently infected
epithelial cell. We use mathematical models to examine the interaction between latent
EBV infection and eﬀector T cells in the development of NPC. Our model predicts
a threshold of the number of eﬀector T cells below which a bifurcation leads to an
increase in the number of latently infected cells. If the probability of developing NPC
is proportional to the number of these EBV latently infected epithelial cells, our model
supports the hypothesis that genetics and diet drive the diﬀerences observed between
the NPC incidence in high risk and low risk populations.
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5.2 Introduction
Persistent infection with the Epstein-Barr virus (EBV) has been associated with
many diseases including diﬀerent types of B cell and epithelial cell cancers such as
Burkitt’s lymphoma, Hodgkin’s lymphoma, and nasopharyngeal carcinoma (NPC) [96].
Within a host, EBV infects two major cell types, B cells and epithelial cells, and can
maintain a latent infection in B cells, within which its genome remains as an episome.
EBV infection of epithelial cells normally results in a lytic infection where viral particles
are released and the cell lyses. Latent infection of epithelial cells, however, occurs in
cases of nasopharyngeal carcinoma (NPC) [70]. NPC is a cancer of epithelial cells that
originates in the pharynx and is classiﬁed into three subtypes (I-III), which refer to
the diﬀerentiation status of the tumor cells. The undiﬀerentiated type III NPC is the
most common and is strongly associated with EBV infection, where all samples have
EBV DNA present.
In latently infected type-III tumor cells, the EBV genome is retained as an episome
in the cell nucleus, not integrated into the host chromosomes [70]. It has been suggested
that genetic changes and consumption of certain carcinogenic foods, such as salted ﬁsh
and preserved foods, predispose epithelial cells to an EBV latent infection [11, 70].
These factors, together with a high prevalence of EBV infection in the populations
of Southeast Asia, southern China, and Mediterranean Africa and in Eskimos of the
Arctic region, are thought to explain the high frequency of NPC in these populations
[5, 70]. NPC incidence rates in these high risk populations can reach up to 40 per
100,000 persons per year for the age group of 45 years old or above, at least 20 times
higher than NPC incidence in a low risk population of North America or Europe [5].
Although these predisposed epithelial cells are susceptible to EBV latent infection,
in vitro studies have shown that EBV remains ineﬃcient at infecting these cells [53].
Intriguingly, immunoglobulin A (IgA) to the EBV viral capsid antigen (VCA), partic-
ularly to the viral glycoprotein 350 (gp350), can enhance EBV infection of cells that
are predisposed [53, 83]. Furthermore, elevated levels of IgA to EBV VCA and gp350
can be observed a few years before the diagnosis of NPC, and have been used as an
early predictor of the onset of this disease [43, 70, 94]. Infection of the predisposed
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epithelial cells gives rise to a pool of latently infected epithelial cells. Expression of
EBV latent genes in these infected cells contribute to increased cell proliferation, cell
survival, and accumulation of regulatory T cells [50, 86], all of which can accelerate
tumor development.
The roles of EBV latent gene expression in NPC have been conﬁrmed[70, 86].
However, most people are infected with EBV at early age and remain healthy carriers
of the virus without symptoms. Immune responses, especially speciﬁc T cells to EBV,
play a key role in the regulation and control of EBV infection in healthy carriers
[33]. EBV infection in immunosuppressed patients, like transplant and HIV infected
individuals, can lead to diﬀerent types of life threatening lymphomas with uncontrolled
proliferation of EBV infected cells [96]. Although T cells can recognize and kill the EBV
latently infected tumor cells [51], genetic factors, like certain human leukocyte antigen
(HLA) types and alteration of EBV latent genes, may aﬀect the ability of T cells to
recognize and kill latently infected epithelial cells [70]. Furthermore, regulatory T cells
(Treg), which can suppress the activation and proliferation of CD8
+ T cells [69, 93],
have also been shown to circulate in the blood and inﬁltrate tumors in NPC patients
[50]. These cells accumulate with age and EBV latent gene expression [19, 86]. Within
the framework of multistage cancer development, it has been suggested that genetic
alteration and diet contribute to the ﬁrst step while EBV latent infection of epithelial
cells in the pharynx is the second step of the pathogenesis of NPC [5]. Our aim is to use
mathematical models to investigate the dynamics of EBV latently infected epithelial
cells to understand the timing of cancer onset.
Mathematical models have been used to study the dynamics of other viruses that
have a latent stage and have strong associations with cancers, including HPV (cervical
cancer), HBV and HCV (liver cancer), and Kaposi’s sarcoma-associated herpesvirus
(Kaposi’s sarcoma) [20, 61, 64, 65, 68]. The dynamics of EBV infection and the T cell
responses have been investigated using simulations of agent-based models, C-ImmSim
and PathSim [9, 78]. We have developed mathematical models to study the dynamics
of EBV, infected cells, T cell responses, and EBV associated infectious mononucleosis
[38, 39]. However, modeling the mechanisms of virus induced cancers remains an open
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ﬁeld. There are as yet no published mathematical models of the association of EBV
infection with cancers.
In this study, we develop a mathematical model that describes the dynamics of EBV
latently infected epithelial cells through the initial two steps of NPC pathogenesis. This
is an adaptation of a model that has been built to describe the dynamics of tumors
being attacked by eﬀector CD8+ T cells [30]. We determine the critical parameters
that aﬀect the dynamics of infected cells and the delay time to tumor development in
NPC patients assuming the risk of developing NPC is proportional to the number of
the latently infected epithelial cells.
5.3 Model
5.3.1 The dynamics of latently infected epithelial cells
Most people infected with EBV are healthy carriers with low, persistent levels of
latent and lytic infections of B cells and epithelial cells [28, 33, 38]. In this study,
we assume the levels of these infections are constant and focus on the dynamics of
latently infected epithelial cells locally in the pharynx. Only predisposed epithelial
cells that may have been genetically altered (EM) can be latently infected by EBV.
These latently infected cells proliferate and die naturally or die from being killed by
eﬀector T cells (Figure 5.1) according to the equation,
dELa
dt




Figure 5.1. Model of latently infected epithelial cells (ELa), arriving from EBV
infection of genetically altered epithelial cells (EM).
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Creation of new latently infected cells depends on existence of EM , the amount of
virus present, and the levels of antibodies to EBV VCA and glycoproteins local to the
pharynx. We assume the existence of a low and constant level of EM that is due to
diet or to genetic alterations. Free virus (V ) and antibodies (A) are also at constant
levels because of the presence of a low and persistent infection of normal B cells and
epithelial cells. New latent infection of epithelial cells is described by
infection = g(A, V )EM , (5.2)
where g(A, V ) is the per cell rate at which EM are latently infected and is an increasing
function of the levels of virus and antibodies. For example, we can set







where μLa is the rate at which EBV successfully establishes a latent infection within
EM , η is the maximal eﬀect of antibodies on the infection eﬃciency of EBV, and α is
the level of antibodies at which the antibody eﬀect is half maximum.
The expression of EBV latent genes promotes cell proliferation. We adapt a model
of tumors being attacked by T cells [30] to build the terms for proliferation and death by
T cell killing in Equation (5.1). We assume a carrying capacity (KE) to the number of








where ρ is the rate of replication of the latently infected epithelial cells.
EBV latent proteins within infected epithelial cells can be recognized by circulating
eﬀector T cells (TLa) during the response to a persistent, latent infection in B cells. We
assume that the total number of TLa remains constant locally at the site of the pharynx
and these cells are in one of two states: free (Tf ) or bind to and in the process of killing
an infected cell (Tb). The eﬃciency of the eﬀector T cell response to latently infected
epithelial cells depends on the rates at which Tf recognize and Tb kill the infected cells,
k1 and k2, respectively (Figure 5.2).
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ELa + Tf Tb Tf + ED
k1 k2
Figure 5.2. The kinetics of eﬀector T cells interacting with EBV latently infected
epithelial cells.
The kinetics of eﬀector T cells in recognizing and killing EBV latently infected
epithelial cells are described by,
dTf
dt
= k2Tb − k1ELaTf (5.4)
dTb
dt
= k1ELaTf − k2Tb. (5.5)
The key assumptions here are Tf + Tb = TLa remains constant and the process of
recognizing an infected cell is much faster than the process of killing one (k1ELa >> k2).
These conditions allow us to further assume the quasi-steady state equilibrium for T ∗b
and derive the equation for the death rate of latently infected epithelial cells that is
due to T cells killing,









Putting the Equations (5.2), (5.3), and (5.6) into Equation (5.1), together with a
constant natural death rate (δE) for ELa, gives a single diﬀerential equation for the
dynamics of latently infected epithelial cells,
dELa
dt








The dynamics of latently infected cells are generally slower than the dynamics of normal
latent and lytic infection. This occurs because of a low eﬃciency of EBV to establish a
latent infection within a genetically altered epithelial cell (g(A, V )), a low replication
rate (ρ), a low eﬃciency of eﬀector T cell killing (k2), and a low natural death rate
(δE) are all low. A summary of parameter deﬁnitions can be found in Table 5.1.
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Table 5.1. Parameter deﬁnitions for the dynamics of latently infected epithelial cells
(Equation 5.7).
Parameter Units Deﬁnition
g(A, V ) 1/day Rate at which EBV successfully establishes
a latent infection within a predisposed
epithelial cell
EM cells Number of genetically altered epithelial cells
ρ 1/day Replication rate of latently infected
epithelial cells
KE cells Carrying capacity of latently infected
epithelial cells
k1 1/(cells · day) Rate at which eﬀector T cells recognize
an infected epithelial cell
k2 1/day Rate at which eﬀector T cells kill
an infected epithelial cell
δE 1/day Death rate of latently infected epithelial cells













ρ− k1δE, and (5.9)
β = k1g(A, V )EM + k2(ρ− δE)− k1k2TLa. (5.10)
The number of positive equilibria and their stability depends on the values of EM ,
and the composite parameters ζ and β. This polynomial has a positive root if EM
is positive, and constant consumption of carcinogenic foods can increase the value of
EM . Increased cell replication and survival that may be promoted by expression of
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EBV latent genes within the infected cells can lead to an increased value of ρ and
a decreased value of δE, respectively. Selection of EBV strains, with change in their
latent proteins, that reduces the eﬃciency of T cell recognition and killing (immune
escape) [70] can lead to decreased values of k1 and k2. An increase in antibodies to the
viral capsid antigen and glycoproteins will increase g(A, V ). Immunosuppression from
an increase in the number of regulatory T cells with age will decrease the value of TLa.
All of these eﬀects lead to increased values of ζ and β.
Treatments that activate latently infected cells to go into lytic replication of virus
within the cells will increase the value of δE. Cell therapy or treatments to improve the
number and functionality of eﬀector T cells responding to EBV latent genes [52, 84, 16]
will increase the value of TLa, k1, and k2. These changes will lead to decreases in the
values of ζ and β.
When ζ < 0, the model has only one stable positive equilibrium. Using Equa-







Since k1KE >> k2, the inequality above is satisﬁed if the replication rate (ρ) is small
or natural death rate (δE) is large. In this case, there is a low number of latently
infected epithelial cells (Figure 5.3(a)). This number increases with β and only attains
a high value when β is large, which can happen in the case of immunosuppression that
decreases the number of TLa.
When ζ > 0, there are critical values of β, β1 and β2, such that multiple solutions
exist for β1 < β < β2 (Figure 5.3(b)). If β < β1, there is only one stable equilibrium
solution of a low level of latently infected cells. For β > β1, there exists another
stable equilibrium solution of a high level of latently infected cells. This high number
of latently infected cells increases with β and becomes the only stable solution when
β > β2. As we have seen, several parameters, including the number of eﬀector T cells








































Figure 5.3. Bifurcation diagrams for the model of latently infected epithelial cells
(Equation 5.7). The solid lines indicate stable solutions and dashed lines indi-
cate unstable solutions. (a) Logarithmic scale of the number of latently infected
epithelial cells at equilibrium (log10(E
∗
La)) as a function of β when ζ < 0. (b)
Logarithmic scale of the number of latently infected epithelial cells at equilibrium
(log10(E
∗
La)) as a function of β when ζ > 0. (c) Logarithmic scale of the num-
ber of latently infected epithelial cells at equilibrium (log10(E
∗
La)) as a function of
TLa when ζ > 0. Parameter values used to compute the bifurcation diagrams:
k1 = 0.007 cells
−1day−1, k2 = 0.007 day
−1, EM = 500 cells, g(A, V ) = 0.0005 day
−1,
KE = 1000 cells. (a) ρ = 0.001 day
−1, δE = 0.01 day
−1. (b) ρ = 0.0033 day−1,
δE = 0.0001 day
−1.
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If the number of eﬀector T cells is small as in the case of immunosuppression (TLa <
T sLa), the latently infected cells can proliferate with little regulation and hence persist
at a high level. If the number of eﬀector cells is large (TLa > T
c
La), these eﬀector cells
can control and maintain a population of latently infected, proliferating epithelial cells
at a low level.
5.3.2 Quasi-steady state approximation of eﬀector T cells
We assume that the eﬀector T cells, which have a short lifespan, have faster
dynamics than the latently infected cells. In our model, we also ﬁx the level of naive T
cells (TN) at constant level. Upon stimulation by latently infected B cells and epithelial
cells, these naive T cells become eﬀector cells (TLa) at rate φ. These eﬀector cells can
proliferate with further stimulation by infected cells with rate θ and die with rate dT ,
where dT > θ. The dependence of T cell activation and proliferation on the available
infected cells takes the saturating functional form,
w(B + ELa) =
B + ELa
K +B + ELa
, (5.12)
where K is the number of infected cells at which activation or proliferation is half
maximal, and B is the constant number of latently infected cells that are close to the
infection site in the pharynx. The dynamics of T cells obey the diﬀerential equation
dTLa
dt
= φw(B + ELa)TN + θw(B + ELa)TLa − dTTLa. (5.13)
A summary of parameter deﬁnition used in the dynamics of eﬀector T cells can be
found in Table 5.2.




dT − θw(B + ELa) . (5.14)
The value of eﬀector T cells can be aﬀected by the number of regulatory T cells (Treg),
which may increase with age, and the level of EBV latent genes being expressed within
the infected cells [19, 86]. Increase in the level of Treg can suppress activation and
proliferation of eﬀector T cells [69, 93], which decreases the values of φ and θ. By
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Table 5.2. Parameter deﬁnitions for the dynamics of eﬀector T cells (Equation 5.13).
Parameter Units Deﬁnition
φ 1/day Rate of eﬀector T cell activation in response
to a latent infection
θ 1/day Rate of eﬀector T cell proliferation
dT 1/day Death rate of eﬀector T cells
B cells Number of latently infected B cells local to the pharynx
K cells Number of infected cells at which T cell activation
and proliferation is half maximal
TN cells Number of naive T cells at the site of the pharynx
substituting Equation (5.14) into Equation (5.7), we obtain the equation describing
the population of latently infected epithelial cells,
dELa
dt








(dT − θw(B + ELa)) − δEELa. (5.15)
5.3.3 Numerical results
We solve Equation (5.15) numerically to investigate the eﬀects of parameters con-
trolling the infection (g(A, V ) or EM), proliferation (ρ), T cell activation (φ), and T
cell recognition of infected cells for killing (k1) on the dynamics of latently infected
epithelial cells (ELa). The number of latently infected cells is maintained at a low level
when there are few predisposed epithelial cells (EM), a low EBV infection or replication
rate, or an eﬃcient T cell response (φ and k1 are high) (Figure 5.4). Variation in these
parameters leads to changes in the dynamics of latently infected cells. For a substantial
range of each parameter, its eﬀects on the dynamics occur only after a long delay, with
the number of latently infected cells remains at a low level for many years before
increasing quickly and approaching a much higher level.
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The dynamics of latently infected cells is especially sensitive to variation in the
rate of T cell activation (φ) (Figure 5.4(c)). Immunosuppression can decrease this
activation rate and, hence, the number of eﬀector T cells responding to the latently
infected cells (Equation 5.14). A small decrease in the value of φ changes changes
equilibrium number of latently infected cells from a very low to a high level.
5.4 Application to the rate of cancer development
The existence of genetically altered or predisposed epithelial cells and EBV infection
of these cells creates the pool of latently infected epithelial cells. Clonal expansion of
one of these cells gives rise to type-III NPC tumors [70]. We assume that the rate of
tumor development (r(t)) is proportional to the number of latently infected epithelial
cells (ELa) within an EBV infected host. This tumor development rate can diﬀer
between individuals or groups of people because of diﬀerences in genetics, diet, and
circulating virus strains. The incidence rates of NPC (the number of new NPC cases
per year per 105 persons) is high in Southern China and Southeast Asia (high risk)
and low in North America and Europe (low risk) [5]. In our model, the rate of tumor
development takes on the form
r(t, p) = σELa(t, p), (5.16)
where σ is the probability rate of developing NPC, and p is a parameter of the model
that can be diﬀerent between individuals.
Genetics and diet are the key features have been hypothesized to drive the diﬀer-
ences in the incidence rates between the high risk and the low risk groups by generating
the predisposed epithelial cells that are susceptible to EBV latent infection. We let
p = g(A, V )EM , which describes the rate of EBV infection of predisposed epithelial
cells to study and compare the rates of getting NPC between groups or population. If






















































































Figure 5.4. Eﬀects of the parameters on the dynamics of latently infected epithelial
cells (ELa). The solid lines show the dynamics of ELa for baseline parameter values while
the dashed lines and dash-dotted lines show the dynamics of ELa for altered values of
the indicated parameters. (a) Variation in the infection rate (g(A, V )) or the number of
predisposed epithelial cells (EM ). (b) Variation in replication rate (ρ). (c) Variation in
the T cell activation rate (φ). (d) Variation in the replication rate at which eﬀector T cells
recognize infected cells for killing (k1). The baseline parameter values used for the simulations
are k1 = 0.007 cells
−1day−1, k2 = 0.007 day−1, EM = 500 cells, g(A, V ) = 0.0005 day−1,
ρ = 0.0033 day−1,KE = 1000 day−1, δE = 0.0001 day−1, φ = 0.0281 day−1,
θ = 0.0468 day−1, dT = 0.125 day−1, B = 500 cells,K = 30000 cells, TN = 10000 cells.
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Assuming p = g(A, V )EM has the Weibull distribution, then the probability distri-










where k is the shape parameter and λ is the scale parameter. We let the mean (E(p)) of
the parameter (p = g(A, V )EM) equal its baseline value, E(p) = λΓ(1+1/k) = 0.0005 ·
500, and analyze the eﬀect of variation in the shape of the probability distribution
function on the incidence of NPC (Figure 5.5).
When k is large (i.e., k = 50), the parameter p = g(A, V )EM has little vari-
ation around its baseline value. Most people in the group or population have low
susceptibility of epithelial cells to EBV latent infection (Figure 5.5(a)). The rate of
developing NPC remains low in this group and only increases modestly with time or
age (Figure 5.5(b)), consistent with the appearance of the age-incidence curves of NPC
observed for the low risk groups [5]. When k is small (i.e., k = 1), the probability
distribution function for p is more spread out. In this case, a greater number of
individuals in the group have a high number of predisposed epithelial cells and higher
(a) (b)





































Figure 5.5. Eﬀects of the shape of the probability distribution function on the
rate of developing NPC. (a) The probability distribution function for k = 1 (solid
line) and k = 50 (dashed line). (b) The NPC incidence rate as a function of
time, with k = 1 (solid line) and k = 50 (dashed line). Parameter values used:
λ = 0.25 (k = 1), λ = 0.253 (k = 50), pmin = 0, pmax = 0.25× 4, σ = 1× 10−5.
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susceptibility of epithelial cells to EBV latent infection (Figure 5.5(a)). The rate of
developing NPC in this group increases steadily and saturates at a high level over time
(Figure 5.5(b)).
5.5 Discussion
We have presented a model describing the dynamics of EBV latently infected
epithelial cells in the pharynx to explore the role of EBV infection in the pathogenesis of
NPC. We show that genetically predisposed epithelial cells that are susceptible to latent
EBV infection produce at least a low level of such infected cells. Genetic alterations
in cells, consumption of carcinogenic foods, and increased levels of IgA antibodies to
EBV antigens can increase the susceptibility of epithelial cells to EBV latent infection,
which is essential to the progression toward NPC.
The expression of EBV latent genes can increase cell proliferation, cell survival,
and accumulation of regulatory T cells [50, 86]. Our model predicts the thresholds of
these eﬀects above which the number of latently infected epithelial cells jumps from
a low to a high level. Type-III NPC tumors have been shown to develop from clonal
expansion of a latently infected epithelial cell [70]. Our model supports a key role for
the expression of EBV latent genes in the pathogenesis of NPC such that these genes
can greatly elevate the number of infected cells and, hence, the risk of developing NPC.
We have adapted a model that describes the dynamics of tumors being attacked by
eﬀector T cells [30]. Our model is simple, keeping track of only one state variable, but
includes regulation of the dynamics of infected cells through infection, proliferation, T
cell response, and cell death. This simple model can capture the long delay between
the initial EBV latent infection of epithelial cells and the time at which the number
of infected cells quickly elevates to a high level (Figure 5.4). Furthermore, with the
additional assumption that the rate of getting NPC is proportional to the number
of latently infected epithelial cell, the model reproduces the measured age-incidence
curves for NPC similar to the appearance of the age-incidence curves of NPC that
have been observed in both low risk and high risk populations.
Numerical results are especially sensitive to variation in the level of eﬀector T cell
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responses. If these model results reﬂect a similar sensitivity to the in vivo dynamics of
infected epithelial cells, treatment that increases eﬀector T cell responses to EBV latent
genes might eﬀectively eliminate tumor cells. However, the accumulation of regulatory
T cells within patients might make the treatment ineﬀective. Also, any factor that
induces immunosuppression in a patient can greatly increase the risk of NPC.
Although our model predicts the threshold value of parameters supporting high
population of latently infected epithelial cells, the quantitative values of these thresh-
olds are not yet conclusive because many other parameters can only be estimated
[38]. The main goal of this study was not to predict the exact values, but rather to
develop a model that includes all the mechanisms of regulation that these parameters
describe. Further studies and analysis of data on latent infection of epithelial cells
in the pharynx, the replication rate of these latently infected cells, and eﬃciency of
eﬀector T cell response are needed to validate both the assumptions and the predictions
of the model.
In vitro studies show IgA to EBV VCA and gp350 can enhance an EBV infection
of epithelial cells [53, 83]. Intriguingly, the levels of IgA greatly increase up to a few
years before the onset of NPC [43]. This elevation of IgA could be induced by EBV.
Positive feedback could be a key to accelerate the development of NPC. Future work
addressing the possibility of positive feedback between the dynamics of IgA and the
latently infected epithelial cells will give insight into the role of elevated IgA levels in
the pathogenesis of NPC.
Our model can also be extended to include a more detailed mechanism of how cell
growth is regulated. A submodel of molecular pathways involved in the expression of
EBV latent genes and how these genes aﬀect the regulation of cell proliferation and
survival could be included to establish a connection between the eﬀects of genetic
alternation at the molecular level and the dynamics of the cell population. EBV
infection is not only associated with NPC, but also other cancers of B cells including
Burkitt’s and Hodgkin’s lymphomas. Understanding the mechanisms of how EBV
latent genes aﬀect the regulation of cell cycles will provide insight into the study of
EBV associated B cell cancers.
85
5.6 Acknowledgements
We would like to thank Dr. Hutt-Fletcher for insightful discussions on Epstein-
Barr virus infection of epithelial cells. Funding for this work was provided by the
National Science Foundation (NSF) Research Training Group (RTG) (Award Number
DMS0354259).
REFERENCES
[1] F.R. Adler and J. Mosquera, Is space necessary? Interference competition and
limits to biodiversity, Ecology 81 (2000), no. 11, 3226–3232.
[2] F.E. Alexander, R.F. Jarrett, R.A. Cartwright, A.A. Armstrong, D.A. Gokhale,
E. Kane, D. Gray, D.J. Lawrence, and G.M. Taylor, Epstein-Barr virus and HLA-
DPB1-*0301 in young adult Hodgkin’s disease, Cancer Epidemiol. Biomarkers
Prev. 10 (2001), no. 6, 705–709.
[3] W.A. Andiman, Epidemiology of primary Epstein-Barr virus infection and infec-
tious mononucleosis, Epstein-Barr Virus (A. Tselis and H.B. Jenson, eds.), vol. 1,
Taylor & Francis Group, New York, NY, 1st ed., 2006, pp. 39–57.
[4] C.M. Borza and L.M. Hutt-Fletcher, Alternate replication in B cells and epithelial
cells switches tropism of Epstein-Barr virus, Nat. Med. 8 (2002), no. 6, 594–599.
[5] F. Bray, M. Haugen, T. Moger, S. Tretli, O.O. Aalen, and T. Grotmol, Age-
incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk
populations and aetiologic implication, Cancer Epidemiol. Biomarkers Prev. 17
(2008), no. 9, 2356–2365.
[6] H.J. Bremermann and H.R. Thieme, A competitive exclusion principle for pathogen
virulence, J. Math. Biol. 27 (1989), no. 2, 179–190.
[7] C.E. Buckley and F.C. Dorsey, Serum immunoglobulin levels throughout the life-
span of healthy man, Ann. Intern. Med. 75 (1971), no. 5, 673–682.
[8] M.F.C Callan, L. Tan, and N. Annels, Direct visualization of antigen-speciﬁc
CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo,
J. Exp. Med. 187 (1998), no. 9, 1395–1402.
[9] F. Castiglione, K. Duca, A. Jarrah, R. Laubenbacher, D. Hochberg, and D.A.
Thorley-Lawson, Simulating Epstein-Barr virus infection with C-ImmSim, Bioin-
formatics 23 (2007), no. 11, 1371–1377.
[10] A. Cerwenka, T.M. Morgan, and R.W. Dutton, Naive, eﬀector, and memory
CD8 T cells in protection against pulmonary inﬂuenza virus infection: homing
properties rather than initial frequencies are crucial, J. Immunol. 163 (1999),
no. 10, 5535–5543.
[11] E.T. Chang and H.O. Adami, The enigmatic epidemiology of nasopharyngeal
carcinoma, Cancer Epidemiol. Biomarkers Prev. 15 (2006), no. 10, 1765–1777.
87
[12] L.S. Chesnokova, S.L. Nishimura, and L.M. Hutt-Fletcher, Fusion of epithelial
cells by Epstein–Barr virus proteins is triggered by binding of viral glycoproteins
gHgL to integrins v6 or v8, Proc. Natl. Acad. Sci. 106 (2009), no. 48, 20464–20469.
[13] N.K. Childers, C. Greeleaf, F. Li, A.P. Dasanayake, W.D. Powell, and S.M.
Michalek, Eﬀect of age on immunoglobulin A subclass distribution in human
parotid saliva, Oral Micr. Immunol. 18 (2003), no. 5, 298–301.
[14] S.C. Clute, L.B. Watkin, M. Cornberg, Y.N. Naumov, J.L. Sullivan, K. Luzuriaga,
R.M. Welsh, and L.K. Selin, Cross-reactive inﬂuenza virus-speciﬁc CD8+ T
cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious
mononucleosis, J. Clin. Invest. 115 (2005), no. 12, 3602–3612.
[15] J.I. Cohen, Clinical aspects of Epstein-Barr virus infection, Epstein-Barr Virus
(E.S. Robertson, ed.), vol. 1, Caister Academic Press, Norfolk, England, 1st ed.,
2005, pp. 35–54.
[16] P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio,
R. Schiavo, S. Secondino, C. Frasson, C. Perotti, M. Moroni, F. Locatelli, and
S. Siena, Cell therapy of stage IV nasopharyngeal carcinoma waith autologous
Epstein-Barr virus targeted cytotoxic T lymphocytes, J. Clin. Oncol. 23 (2005),
no. 35, 8942–8949.
[17] T. Cotner and Pious D., HLA-DR beta chains enter into an aggregated complex
containing GRP-78/BiP prior to their degradation by the pre-Golgi degradative
pathway, J. Biol. Chem. 270 (1995), no. 5, 2379–2386.
[18] M. Davenport, C. Fazou, A.J. McMichael, and M.F.C. Callan, Clonal selection,
clonal senescence, and clonal succession: the evolution of the T cell response to
infection with a persistent virus, J. Immunol. 168 (2002), no. 7, 3309–3317.
[19] C. Dejaco, C. Dufner, and M. Schirmer, Are regulatory T-cells linked with aging?,
Exp. Gerontol. 41 (2006), no. 4, 339–345.
[20] G.M. Depler, H.K. Nguyen, J. Webster-Cyriaque, and H.T. Banks, A dynamic
model for induced reactivation of latent virus, J. Theor. Biol. 244 (2007), no. 3,
451–462.
[21] J.M.B. Edwards and M. Woodroof, EB virus-speciﬁc IgA in serum of patients with
infectious mononucleosis and of healthy people of diﬀerent ages, J. Clin. Pathol.
32 (1979), no. 10, 1036–1040.
[22] M.A. Epstein, The origins of EBV research: discovery and characterization of the
virus, Epstein-Barr Virus (E.S. Robertson, ed.), vol. 1, Gaister Academic Press,
Norfolk, England, 1st ed., 2005, pp. 1–14.
[23] P.J. Farrell, Role for HLA in susceptibility to infectious mononucleosis, J. Clin.
Invest. 117 (2007), no. 10, 2756–2758.
88
[24] E.B. Griﬃn and R. Rochford, Endemic Burkitt’s lymphoma, Epstein-Barr Virus
(Robertson E.S., ed.), vol. 1, Caister Academic Press, Norfolk, England, 1st ed.,
2005, pp. 113–137.
[25] A.O. Guerreiro-Cacais, L. Li, D. Donati, M.T. Bejarano, A. Morgan, M.G.
Masucci, L.M. Hutt-Fletcher, and V. Levitsky, Capacity of Epstein-Barr virus
to infect monocytes and inhibit their development into dendritic cells is aﬀected
by the cell type supporting virus replication, J. Gen. Virol. 85 (2004), no. 10,
2767–2778.
[26] K.M. Haan, W.W. Kwok, R. Longnecker, and P. Speck, Epstein-Barr virus entry
utilizing HLA-DP or HLA-DQ as a coreceptor, J. Virol. 74 (2000), no. 5, 2451–
2454.
[27] K.M. Haan and R. Longnecker, Coreceptor restriction within the HLA-DQ locus
for Epstein-Barr virus infection, PNAS 97 (2000), no. 16, 9252–9257.
[28] V. Hadinoto, M. Shapiro, C.C. Sun, and D.A. Thorley-Lawson, The dynamics of
EBV shedding implicate a central role for epithelial cells in amplifying viral output,
PLos Pathogens 5 (2009), no. 7, 1–15.
[29] J.M. Heﬀernan, R.J. Smith, and L.M. Wahl, Perspectives on the basic reproductive
ratio, J.R. Soc. Interface 2 (2005), no. 4, 281–293.
[30] J.R. Hiernaux and R. Lefever, Population dynamics of tumors attacked by im-
munocompetent killer cells, Theoretical immunology II (A.S. Perelson, ed.), vol. 2,
Addison Wesley, New York, 1st ed., 1988, pp. 19–35.
[31] A. Hildesheim, R.J. Apple, C.J. Chen, S.S¿ Wang, Y.J. Cheng, W. Klitz, S.J.
Mack, I.H. Chen, M.M. Hsu, C.S. Yang, L.A. Brinton, P.H. Levine, and H.A.
Erlich, Association of HLA class I and II alleles and extended haplotypes with
nasopharyngeal carcinoma in Taiwan, J. Natl. Cancer Inst. 94 (2002), no. 23,
1780–1789.
[32] A.D. Hislop, N.E. Annels, N.H. Gudgeon, A.M. Leese, and A.B. Rickinson,
Epitope-speciﬁc evolution of human CD8+ T cell responses from primary to
persistent phases of Epstein-Barr virus infection, J. Exp. Med. 195 (2002), no. 7,
893–905.
[33] A.D. Hislop, G.S. Taylor, D. Sauce, and A.B. Rickinson, Cellular responses to
viral infection in humans: lessons from Epstein-Barr virus, Annu. Rev. Immunol.
25 (2007), no. 1, 587–617.
[34] H. Hjalgrim, J. Asking, K. Rostgaard, S. Hamilton-Dutoit, F.R.C. Path, M. Frisch,
J. Zhang, M. Madsen, N. Rosdahl, H.B. Konradsen, H.H. Storm, and M. Melbye,
Characteristics of Hodgkin’s lymphoma after infectious mononucleosis, N. Engl. J.
Med. 349 (2003), no. 14, 1324–1332.
89
[35] D. Hochberg, T. Souza, M. Catalina, J.L. Sullivan, K. Luzuriaga, and D.A.
Thorley-Lawson, Acute infection with Epstein-Barr virus targets and overwhelms
the peripheral memory B-cell compartment with resting, latently infected cells, J.
Virol. 78 (2004), no. 10, 5194–5204.
[36] L.M. Hutt-Fletcher, EBV entry and epithelial infection, Epstein-Barr Virus
(Robertson E.S., ed.), vol. 1, Caister Academic Press, Norfolk, England, 1st ed.,
2005, pp. 359–378.
[37] L.M. Hutt-Fletcher, Epstein-Barr virus entry, J. Virol. 81 (2007), no. 15, 7825–
7832.
[38] G.T. Huynh and F.R. Adler, Alternating host cell tropism shapes the persistence,
evolution and coexistence of Epstein-Barr virus infections in human, B. Math.
Biol. In-press, (2010).
[39] G.T. Huynh and F.R. Adler, Mathematical modeling the age dependence of
Epstein-Barr virus associated infectious mononucleosis. Manuscript submitted for
publication, (2010).
[40] A. Imrie, J. Meeks, A. Gurary, M. Sukhbataar, P. Kitsutani, P. Eﬄer, and Z. Zhao,
Diﬀerential functional avidity of dengue virus-speciﬁc T-cell clones for variant
peptides represeting heterologous and previously encountered serotypes, J. Virol.
81 (2007), no. 18, 10081–10091.
[41] B.F. Israel and S.C. Kenney, EBV lytic infection, Epstein-Barr Virus (Robertson
E.S., ed.), vol. 1, Caister Academic Press, Norfolk, England, 1st ed., 2005, pp. 571–
612.
[42] A. Jafarzadeh, A. Mostafaie, M. Sadeghi, M. Nemati, M.T. Rezayati, and G. Has-
sanshahi, Age-dependent changes of salivary IgA and IgE levels in healthy subjects,
Dent. Res. J. 5 (2008), no. 2, 89–93.
[43] M.F. Ji, D.K. Wang, Y.L. Yu, Y.Q. Guo, J.S. LIang, W.M. Cheng, Y.S. Zong,
K.H. Chan, S.P. Ng, W.I. Wei, D.T.T. Chua, J.S.T. Sham, and M.H. Ng,
Sustained elevation of Epstein-Barr virus antibody level preceding clinical onset
of nasopharyngeal carcinoma, Br. J. Cancer 96 (2007), no. 4, 623–630.
[44] R. Jiang, R.S. Scott, and L.M. Hutt-Fletcher, Epstein-Barr virus shed in saliva is
high in B-cell-tropic gp42, J. Virol. 80 (2006), no. 14, 7281–7283.
[45] L. Jones and A. Perelson, Opportunistic infection as a cause of transient viremia
in chronically infected HIV patients under treatment with HAART, B. Math. Biol.
67 (2005), no. 6, 1227–1251.
[46] R.M. Kedl and M.F. Mescher, Qualitative diﬀerences between naive and memory
T cells make a major contribution to the more rapid and eﬃcient memory CD8+
T cell response, J. Immunol. 161 (1998), no. 2, 674–683.
90
[47] A.N. Kirschner, A.S. Lowrey, R. Longnecker, and T.S. Jardetzky, Binding-site
interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal
a peptide that inhibits both epithelial and B-cell membrane fusion, J. Virol. 81
(2007), no. 17, 9216–9229.
[48] A.N. Kirschner, J. Sorem, R. Longnecker, and T.S. Jardetzky, Structure of
Epstein-Barr virus glycoprotein 42 suggests a mechanism for triggering receptor-
activated virus entry, Cell Press 17 (2009), no. 2, 223–233.
[49] L.L. Laichaalk, D. Hochberg, G.J. Babcock, R.B. Freeman, and D.A. Thorley-
Lawson, The dispersal of mucosal memory B cells: evidence from persistent EBV
infection, Immunity 16 (2002), no. 5, 745–754.
[50] K.M. Lau, S.H. Cheng, S.A. Lo, J.K. Woo, and C.A. Van Hasselt, Increase in
circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma
patients, Br. J. Cancer 96 (2007), no. 4, 617–622.
[51] S.P. Lee, A.T.C. Chan, S. Cheung, W.A. Thomas, D. CroomCarter, C.W. Dawson,
C. Tsai, S. Leung, P.J. Johnson, and D.P. Huang, CTL control of EBV in
nasopharyngeal carcinoma (NPC): EBV-speciﬁc CTL responses in the blood and
tumors of NPC patients and the antigen-processing function of the tumor cells, J.
Immunol. 36 (2000), no. 1, 573–582.
[52] C. Lin, W. Lo, T. Lee, Y. Ren, S. Hwang, Y. Cheng, C. Chen, Y. Chang, S.P. Lee,
A.B. Rickinson, and P.K.H. Tam, Immunization with Epstein-Barr virus (EBV)
peptide-pused dendritic cells induces functional CD8+ T cell immunity and may
lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma,
Cancer Res. 62 (2002), no. 23, 6952–6958.
[53] J. Liu, L. Cassar, A. Pinto, and H. Li, Mechanisims of cell immortalization
mediated by EB viral activation of telomerase in nasopharyngeal carcinoma, Cell
Research 16 (2006), no. 10, 809–817.
[54] D.C. Macallan, D.L. Wallace, Y. Zhang, H. Ghattas, B. Asquith, C. Lara,
A. Worth, G. Panayiotakopoulos, G.E. Griﬃn, D.F. Tough, and P.C. Beverley,
B-cell kinetics in humans: rapid turnover of peripheral blood memory cells, Blood
105 (2005), no. 9, 3633–3640.
[55] M.G. Masucci, Epstein-Barr virus oncogenesis and the ubiquitin-proteasome sys-
tem, Oncogene 23 (2004), no. 11, 2107–2115.
[56] K.A. McAulay, C.D. Higgins, K.F. Macsween, A. Lake, R.F. Jarrett, F.L. Robert-
son, H. Williams, and D.H. Crawford, HLA class I polymorphisms are associatd
with development of infectious mononucleosis upon primary EBV infection, J.
Clin. Invest. 117 (2007), no. 10, 3042–3048.
[57] E.S. Mocarski, T. Shenk, and R.F. Pass, Cytomegaloviruses, Field’s Virol (D.M.
Knipe and Howley P.M, eds.), vol. 2, Lippincott Williams and Wilkins, Philadel-
phia, PA, 5th ed., 2007, pp. 2701–2772.
91
[58] J. Mosquera and F.R. Adler, Evolution of virulence: a uniﬁed framework for
coinfection and superinfection, J.Theor.Biol 195 (1998), no. 3, 293–313.
[59] M.M. Mullen, K.M. Haan, R. Longnecker, and T.S. Jardetzky, Structure of
Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1, 9
(2002), no. 2, 375–385.
[60] C. Munz, Immune response and evasion in the host-EBV interaction, Epstein-Barr
Virus (Robertson E.S., ed.), vol. 1, Caister Academic Press, Norfolk, England, 1st
ed., 2005, pp. 197–231.
[61] A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden,
and A.S. Perelson, Hepatitis C viral dynamics in vivo and the antiviral eﬃcacy of
interferon-alpha therapy, Science 282 (1998), no. 5386, 103–107.
[62] J.C. Niederman and A.S. Evans, Epstein-Barr Virus, Infections of humans: epi-
demiology and control (A.S. Evans and R.A. Kaslow, eds.), vol. 1, Plenum Medical
Book Co., New York, 4th ed., 1997, pp. 253–282.
[63] S. Nikiforow, K. Bottomly, and G. Miller, CD4+ T-cell eﬀectors inhibit Epstein-
Barr virus-induced B-cell proliferation, J. Virol. 75 (2001), no. 8, 3740–3752.
[64] M.A. Nowak and C.R. Bangham, Population dynamics of immune responses to
persistent viruses, Science 272 (1996), no. 5258, 74–79.
[65] M.A. Nowak, S. Bonhoeﬀer, A.M. Hill, R. Boehme, H.C. Thomas, and H. McDade,
Viral dynamics in hepatitis B virus infection, Proc. Natl. Acad. Sci. 93 (1996),
no. 9, 4398–4402.
[66] M.A. Nowak and R.M. May, Virus dynamics: Mathematical principles of im-
munology and virology, 1st ed., Oxford, New York, USA, 2000.
[67] H. Oberender, E. Straube, M. Kunkel, L. Gartner, and I. Morﬁadakis, Epstein-
Barr virus-speciﬁc immunoglobulin A in patients with infectious mononucleosis, an
age-dependent factor, Eur. J. Clin. Microbiol. Infect. Dis. 5 (1986), no. 2, 173–174.
[68] A.S. Perelson, Modeling viral and immune system dynamics, Nat. Reviews Im-
munol. 2 (2002), no. 1, 28–36.
[69] C.A. Piccirillo and E.M. Shevach, Cutting edge: control of CD8+ T cell activation
by CD4+CD25+ immunoregulatory cells, J. Immunol. 167 (2001), no. 3, 1137–
1140.
[70] N. Raab-Traub, Epstein-Barr virus in the pathogenesis of NPC, Epstein-Barr
Virus (E.S. Robertson, ed.), vol. 1, Caister Academic Press, Norfolk, England,
1st ed., 2005, pp. 71–92.
[71] M.E. Ressing, D. van Leeuwen, F.A.W. Verreck, S. Keating, R. Gomez, K.L.M.C.
Franken, T.H.M. Ottenhoﬀ, M. Spriggs, T.N. Schumacher, L.M. Hutt-Fletcher,
M. Rowe, and E.J.H.J. Wiertz, Epstein-Barr virus gp42 is posttranslationally
92
modiﬁed to produce soluble gp42 that mediates HLA class II immune evasion,
J. Virol. 79 (2005), no. 2, 841–852.
[72] A. Rickinson, Epstein-Barr virus: Summary, conclusion and forward look, vol. 1,
Caister Academic Press, Norfolk, England, 2005, pp. 711–753.
[73] A. Rickinson and E. Kieﬀ, Epstein-Barr virus, Field’s Virol (B.N. Fields, D.M.
Knipe, and Howley P.M, eds.), vol. 2, Lippincott-Raven, Philadelphia, PA, 3rd
ed., 1996, pp. 2397–2446.
[74] A. Rickinson and E. Kieﬀ, Epstein-Barr Virus, Field’s Virol (D.M. Knipe and
Howley P.M, eds.), vol. 2, Lippincott Williams and Wilkins, Philadelphia, PA,
4th ed., 2001, pp. 2575–2627.
[75] E.S. Robertson (ed.), Epstein-Barr virus, 1st ed., vol. 1, Caister Academic Press,
Norfolk, England, 2005.
[76] D. Sauce, M. Larsen, S.J. Curnow, A.M. Leese, and P.A. Moss, EBV-associated
mononucleosis leads to long-term global deﬁcit in T cell responsiveness to IL-15,
Blood 108 (2006), no. 1, 11–18.
[77] L.K. Selin, S.M. Varga, I.C. Wong, and R.M. Welsh, Protective heterologous
antiviral immunity and enhanced immunopathogenesis mediated by memory T cell
populations, J. Exp. Med. 188 (1998), no. 9, 1705–1715.
[78] M. Shapiro, K.A. Duca, K. Lee, E. Delgado-Eckert, J. Hawlins, A.S. Jarrah,
R. Laubenbacher, R. Laubenbacher, N.F. Polys, V. Hadinoto, and D.A. Thorley-
Lawson, A virtual look at Epstein-Barr virus infection: Simulation mechanism, J.
Theor. Biol. 252 (2008), no. 4, 633–648.
[79] P.L. Shaw, A.N. Kirschner, T.S. Jardetzky, and R. Longnecker, Characteristics of
Epstein-Barr virus envelope protein gp42, Virus Genes 40 (2010), no. 3, 307–319.
[80] S.L. Silins, M.A. Sherritt, J.M. Silleri, S.M. Cross, S.L. Elliott, M. Bharadwaj,
T.T. Le, L.E. morrison, R. Khanna, D.J. Moss, A. Suhrbier, and I.S. Misko,
Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood
T-cell repertoire perturbations despite high levels of systemic viral load, Blood 98
(2001), no. 13, 3739–3744.
[81] A.L. Silva, J. Omerovic, T.S. Jardetzky, and R. Longnecker, Mutational analyses
of Epstein-Barr virus glycoprotein 42 reveal functional domains not involved in
receptor binding but required for membrane fusion, J. Virol. 78 (2004), no. 11,
5946–5956.
[82] D. Sitki-Green, M. Covington, and N. Raab-Traubb, Compartmentalization and
transmission of multiple Epstein-Barr virus strains in asymptomatic carriers , J.
Virol. 77 (2003), no. 3, 1840–1847.
[83] J.W. Sixbey and Q.Y. Yao, Immunoglobulin A-induced shift of Epstein-Barr virus
tissue tropism, Science 255 (1992), no. 5051, 1578–1580.
93
[84] K.C.M. Straathof, C.M. Boolard, U. Popat, M.H. Huls, T. Lopez, M.C. Morriss,
M.V. Gresik, A.P. Gee, H.V. Russell, M.K. Brenner, C.M. Rooney, and H.E.
Heslop, Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-spciﬁc T
lymphocytes, Blood 105 (2005), no. 5, 1898–1904.
[85] D.A. Thorley-Lawson, EBV persistence and latent infection in vivo, Epstein-Barr
Virus (Robertson E.S., ed.), vol. 1, Caister Academic Press, Norfolk, England, 1st
ed., 2005, pp. 309–349.
[86] S.W. Tsao, K.W. Lo, and D.P. Huang, Nasopharyngeal carcinoma, Epstein-Barr
Virus (A. Tselis and H.B. Jenson, eds.), vol. 1, Taylor and Francis Group, New
York, 1st ed., 2006, pp. 273–295.
[87] S.M. Turk, R. Jiang, L.S. Chesnokova, and L.M. Hutt-Fletcher, Antibodies to
gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells, J.
Virol. 80 (2006), no. 19, 9628–9633.
[88] P. van den Driessche and J. Watmough, Reproduction numbers and sub-threshold
endemic equilibria for compartmental models of disease transmission, Math.
Biosci. 180 (2002), no. 1-2, 29–48.
[89] H. Veiga-Fernandes, U. Walter, C. Bourgeois, A. McLean, and B. Rocha, Response
of naive and memory CD8+ T cells to antigen stimulation in vivo, Nature
Immunol. 1 (2000), no. 1, 47–53.
[90] G. Wang, G.R.F. Krueger, and L.M. Buje, Mathematical model to simulate the cel-
lular dynamics of infection with human herpesvirus-6 in EBV-negative infectious
mononucleosis, J. Med. Virol. 71 (2003), no. 4, 569–577.
[91] D. Weber-Mzell, P. Kotanko, A.C. Hauer, U. Goriup, J. Haas, N. Lanner, W. Erwa,
I.A. Ahmaida, S. Haitchi-Petnehazy, M. Stenzel, G. Lanzer, and J. Deutsch,
Gender, age and seasonal eﬀects on IgA deﬁciency: a study of 7293 Caucasians,
Euro. J. Clin. Invest. 34 (2004), no. 3, 224–228.
[92] D. Wodarz, S. Sierro, and P. Klenerman, Dynamics of killer T cell inﬂation in
viral infections, J.R.S. Interface 4 (2007), no. 14, 533–543.
[93] E.Y. Woo, H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Riley, L.R. Kaiser,
and C.H. June, Cutting edge: regulatory T cells from lung cancer patients directly
inhibit autologous T cell proliferation, J. Immunol. 168 (2002), no. 9, 4272–4276.
[94] J.W. Xu, A. Ahmad, and J. Menezes, Clinical relevance of serum immunoglobulin
A antibodies to Epstein-Barr virus envelope glycoprotein gp350 in nasopharyngeal
carcinoma patients, J. Clin. Microbiol. 36 (1998), no. 12.
[95] K. Yamanishi, Y. Mori, and P.E. Pellett, Human herpesviruses 6 and 7, Field’s
Virol (D.M. Knipe and Howley P.M, eds.), vol. 2, Lippincott Williams andWilkins,
Philadelphia, PA, 5th ed., 2007, pp. 2701–2772.
94
[96] L.S. Young and A.B. Rickinson, Epstein-Barr virus: 40 years on, Nat. Rev. Cancer
4 (2004), no. 10, 757–768.
